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Abstract
As of 2018, the United States National Institutes of Health estimate that over half a
billion people worldwide are affected by autoimmune disorders. Though these conditions are
prevalent, treatment options remain relatively poor, relying primarily on various forms of
immunosuppression which carry potentially severe side effects and often lose effectiveness
overtime. Given this, new forms of therapy are urgently needed. We propose smallinterfering RNA (siRNA) for hypervariable regions of the T-cell receptor β-chain gene
(TCRb) as a highly targeted, novel means of therapy for the treatment of autoimmune
disorders.
In this experiment, both human Jurkat and human CD8+ anti-HPV T-cells were
purchased and their mRNA isolated. A novel method for the production of siRNA was then
employed to create an siRNA “cocktail” for particular hypervariable regions within TCRb.
Additionally, a conventional method was employed to create siRNA for single
computationally determined regions of TCRb. Synthesized siRNA was subsequently coated
with lipofectamine to facilitate transfection. The coated siRNAs were then applied to
respective patient cells at 10 pmol for 24h. Gene knockdown was quantified by qPCR, while
cell viability was quantified by MTS assay and trypan blue count.
While all siRNA species demonstrated a significant level of knockdown on TCRb,
CD3, and CD137 (P < 0.05), the siRNA “cocktail” showed the highest level of TCRb
knockdown (P = 0.0406). Moreover, siRNA developed in this manner had an extremely
small effect on T-cells lacking affinity for different antigens (low off targeting). The effect
of each treatment on cell viability was not statistically significant (For all comparisons, P >
0.2).
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The results of this experiment demonstrate not only the high potency of the described
siRNAs on gene knockdown, but the low levels of off-targeting they exhibit. Based on this,
we believe that both the previously described siRNA cocktail as well as computationally
created siRNAs could potentially be utilized as effective therapeutics in the treatment of
autoimmunity.
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Chapter 1. Introduction
As of 2018, the United States National Institutes of Health (NIH) estimate that over half a
billion people worldwide are affected by various autoimmune conditions (NIH, 2018). These
conditions range from cosmetic disorders (such as psoriasis), to potentially life-threatening
diseases (such as lupus). In addition to presenting in a wide range of severity, the financial
burden put onto patients with these conditions varies widely as well. In the case of a relatively
mild condition such as psoriasis, the financial burden on a patient actively getting treatment for
the condition can be as low as $1757 annually (Evans, 2016). Though this is certainly not an
insubstantial financial burden, it contrasts heavily with conditions such as multiple sclerosis,
lupus, or Crohn’s disease. The annual cost of conditions such as these easily exceed $60,000 per
year for many patients, with the majority of this cost being composed of direct medical expenses
(Optum Health, 2019).
Over the past few decades, there have been many advances in the field of molecular
biology, particularly in the area of its application to medicine. One of the most impactful of these
technologies over these years has come from the advent of RNA interference (RNAi) technologies
(Daneholt, 2006). RNA interference is a process by which specific genes are effectively silenced
with short strands of inhibitory RNA molecules (Daneholt, 2006). One type of RNA molecule
which has been shown to effectively accomplish this is small interfering RNA (siRNA) (Agrawal
et al, 2003). The first step of siRNA creation involves the synthesis of a strand of double stranded
RNA (dsRNA), and subsequently enabling its entrance into the cytoplasm of a mammalian cell
(Agrawal et al, 2003). Upon entering a cell, this dsRNA is shortly thereafter bound by the protein
DICER, which cleaves the dsRNA into siRNA (Agrawal et al, 2003). Key features of the resulting
siRNA molecules are their typical length of 21-25 nucleotides, as well as a pair of overhanging

nucleotides on both 3’ ends, hydroxylated 3’ ends, and phosphorylated 5’ ends (Agrawal et al,
2003). After the siRNA has been formed, RNA-induced silencing complex (RISC) loads a single
strand (typically the antisense strand) into its complex (Agrawal et al, 2003). The loaded RISC
then proceeds to bind messenger RNA (mRNA) strands complimentary to the loaded siRNA
strand, cleaving and inactivating the mRNA in the process (Agrawal et al, 2003). This disruption
in translation leads to silencing of the target gene as the proteins it codes for will ultimately not be
created.
In 1999, when the effects of siRNA were first reported, its potential medical applications
were immediately evident (Baulcombe, 1999). As the genes for DICER are relatively conserved
among mammals, the gene silencing effects of siRNA potentially allow for treatment of diseases
in which a human’s own cells are responsible for all of, or part, of the pathology. This includes
conditions ranging from cancer, autoimmunity, or even some viral infections. In fact, not
surprisingly, in the past decade there have arisen clinical trials for drugs which utilize siRNA in
the treatment of cancer, as well as, Ebola (Oha and Parkb, 2009). Unfortunately, the research for
use of RNAi technologies in autoimmune diseases has been relatively sparse, likely owing
primarily to the mechanism by which autoimmune diseases cause their pathology. Autoimmune
disease pathology is caused by a small minority of immune cells acting in such a way that causes
damage to the host (Harrison's Principles of Internal Medicine, 2012). Unfortunately, the
differences between the cells causing autoimmune pathology versus those which are necessary for
normal biological function and immunity are scarce. As a result, most RNAi therapies which seek
to alleviate or eliminate a particular pathology will also end up causing damage to the healthy
portion of the host’s immune system. As a result, therapies for autoimmune diseases which seek
to use RNAi technology will typically target genes which are significantly up-regulated as part of
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the condition’s pathology, such as pro-inflammatory factors in rheumatoid arthritis (Pauley and
Cha, 2013). This being the case, the ideal target for treatment of an autoimmune disorder would
be a gene expressed exclusively in the cell lines responsible for the pathology of the condition.
Fortunately, there are a few genes that produce mRNA which differ between individual immune
cell lines. These include the genes responsible for antibody production in B cells as well as antigen
receptor chain production in T cells (Janeways immunobiology, 2012).
To deal with the vast array of pathogens which are able to infect humans, the body has
evolved a remarkable system commonly referred to as adaptive immunity. In contrast with the
innate immune system, the adaptive immune system has evolved to be able to deal with novel
pathogens, allowing the body to rid itself of diseases not experienced by previous generations
(Janeways immunobiology, 2012). This is achieved by the generation of variation in antigen
recognition chains for T cells, and antibodies for B cells, a process which occurs in a series of steps
which over the past century have become fairly well understood. Though the processes are
extremely similar, for the sake of time, focus will be taken on antigen receptor chain in T cells (as
they are more relevant to the scope of these writings).
To understand the gene arrangement coding for antigen receptor chain development, one
must first understand the structure of the chains themselves. In 95% of cases, a T cell receptor is
composed of both an alpha, and a 𝛽 chain (Janeways immunobiology, 2012). Each of these chains
is formed by an amino terminal variable (V) region, which composes the antigen recognition
portion of the receptor, and a constant (C) region, which composes the transmembrane portion of
the receptor (Janeways immunobiology, 2012). Though the processes which govern the
development of both of these chains are similar, the development of the β chain will be the focus
of this chapter (the chain most pertinent in this experiment).
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Development of the β chain is controlled by a gene segment designed to create the
opportunity for a large degree of diversity for the antigen receptor it will ultimately encode. The β
chain is composed of many of each of four separate segment types: variable (V) regions, joining
(J) segments, diversity (D) segments, and constant (C) segments. These genes are arranged in an
order as follows: 52 V regions, followed by a D region, followed by 6 J segments, followed by a
C region, followed by an additional D region, followed by 7 additional J segments, followed by a
final C region (Janeways immunobiology, 2012). The genes encoding the β chain receptor are
located on chromosome 7 (Caccia et al, 1984). To produce a functional β chain, the variable,
diversity, and joining regions undergo rearrangement and splicing to one another through a series
of processes. This newly spliced gene is then linked to the constant gene regions to form the
completed gene product which will ultimately produce the mRNA responsible for β chain
production (Janeways immunobiology, 2012). Because of this series of gene recombinations, it is
highly unlikely that the gene segment encoding for any two separate lines of T cells will be the
same.
The proliferation of both B and T cells is dependent on how effective they are at
recognizing antigen. With some exception, cells which successfully recognize antigen receive a
variety of signals which stimulate their proliferation (Janeways immunobiology, 2012). Cells that
do not receive these signals, however, tend not to reproduce and over time begin to die off
(Janeways immunobiology, 2012). The lifespan of these cells ranges greatly, with the half-life of
CD8 T cells being around 37 days (McDonagh and Bell, 1995) while their CD4 counterparts have
been shown to survive for as long as 17 years in humans (Imamishi et al, 2014).
The gene rearrangements that cause the diversity seen in both T and B cells are an
evolutionary necessity for the destruction of a variety of pathogens. These same rearrangements,
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however, can potentially be problematic for the wellbeing of the same system they are trying to
protect, as is the case in autoimmune disorders. Autoimmune disorders are caused when B or T
cell receptors become specific for motifs on the host’s own tissues (Janeways immunobiology,
2012). These tissue molecules which are targeted are termed autoantigens, and can vary greatly
between individuals. The immune system has a number of mechanisms, as well as a vetting
process, designed to prevent the occurrence of autoantigen (Janeways immunobiology, 2012). This
being the case, however, given the rate at which new cells are produced, even a small slip in the
system can lead to autoimmunity. An example of a disease in which this occurs is multiple
sclerosis. In the case of multiple sclerosis, T cells gain specificity for protein present in the myelin
sheath, the protective and insulative coating found surrounding neurons (Huseby et aI, 2012). The
recognition of myelin by a T cell causes inflammation as well as a disruption of the blood-brain
barrier, leading to a variety of severely damaging neurological effects for the victim (Minager and
Alexander, 2003).
Though significant advances in autoimmune disease treatment have been made over the
past several decades, there is a large requirement for improvement. Most current therapies focus
on down regulation of the immune system as a whole, as opposed to targeting the specific immune
cell lines causing the pathology. As expected, this leads to a variety of problems and side effects,
including global immune suppression. These side effects severely limit the dosing of these drugs,
as high and long-term use of these therapies can ultimately lead to the patient’s immune system
becoming severely compromised (Williamson and Berger, 2015). It is therefore critical that
treatments which are highly specific for the agents causing the specific pathology be the primary
focus of the development of future therapies targeted at autoimmune disorders.
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To develop therapies with high specificity, it is necessary to be able to identify and exploit
the subtle differences between cells. In the case of autoimmune disorders, this means
differentiating between specific lines of B or T cells. Given that there is genetic diversity among
these lines in the form of the genes encoding the receptors found on their surfaces, these same
genetic differences offer a viable target for the creation of a therapy with a high degree of
specificity. Given that RNAi technology gives scientists the ability to target specific gene
sequences with relatively high fidelity, RNAi can likely offer a highly effective means of treating
a wide array of autoimmune disorders, provided the ability to elucidate the gene sequences
required for B cell and T cell receptor production.
Therapy with a method as specific as RNAi in autoimmune conditions also has a number
of other implications. If the cells lines affected by RNAi are unable to produce antigen receptors,
they will, therefore, be unable to recognize antigen. A cell which is unable to recognize antigen
will not receive proliferation signals, and slowly will begin to die off. This being the case, RNAi
may potentially offer a means of therapy which can lead to remission of autoimmune diseases over
time, as the cell lines causing the pathology may gradually begin to die off. This contrasts greatly
with most current therapies, which show a high degree of relapse soon after treatment has been
halted. This research aims to develop the methods required to synthesize siRNA for the T cell
receptor beta chain (TCRb gene). Additionally, this research seeks to test the various siRNA
species created on human immune cells ex-vivo to demonstrate their effectiveness.
Notes
1. Agrawal, N., Dasaradhi, P., Mohmmed, A., Malhotra, P., Bhatnagar, R., Mukherjee, S.
2003. “RNA Interference: Biology, Mechanism, and Applications”. Microbiol Mol Biol
Rev. 67(4): 657-685.
2. “Autoimmune Diseases.” NIH, U.S. Department of Health and Human Services, 2018,
www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm.
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Chapter 2. The 51 Primer Method
2.1 Introduction
To Create siRNA Targeting the TCRb gene of a particular line of T cells, it is necessary
to know the mRNA sequence of the TCRb gene within these cells. Though this may seem simple
in principle, it presents quite a technical challenge due to the high levels of variation that occur
within this gene. For a researcher to be able to sequence a gene, they must first amplify the gene
to sufficient levels for analysis using Polymerase chain reaction (PCR). Unfortunately, one of the
requirements to carry out a successful PCR reaction is designing primers targeting sequences
bracketing the gene of interest. Unfortunately, due to the high levels of variation within the
TCRb gene, this is not possible using conventional methods. As previously discussed, there are
roughly 52 different variable regions which can be found on the 5’ end of the mRNA for the
TCRb gene. Additionally, there are two different variations (though highly similar) of the
constant region found on the 3’ end of the mRNA. Given this information, a conventional
method used for the amplification of the TCRb gene has been to make two separate primer
mixes, one containing primers for the 51 variable regions and the other containing primers for
both of the constant region variants. One benefit of this method is the relative ease of
amplification once the primer mixes have been created (given that a large number of aliquots can
be made). Additionally, though many primers are required, these primers are extremely
inexpensive (costing only approximately $6 USD at the time of this writing) and come in
quantities that can be used to perform hundreds of assays.
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2.2 Methods
The methods used in this experiment were adapted from Robins et al. The primers used
were taken from United States Patent Application: US 2016/0319340 A1. These Primers as well
as primer pCB1 can be found in appendix A.
2.2.1 Creation of Primer Mix
Primers were ordered dry and desalted from Thermo Scientific and resuspended to a
concentration of 200mM. One microliter of each of the 51 variable region primers were
combined on ice and pipetted gently to mix. In a second microfuge tube, pCB1 primer (a primer
which binds to both potential constant regions) was resuspended to 10mM.
2.2.2 mRNA Isolation
RNA was isolated from Both Human Jurkat and Human CD8+ anti-HPV cells. This was
accomplished using an Absolutely RNA Nanoprep Kit (Agilent). Approximately 10,000 cells of
each sample were combined with 100 μl lysis buffer and 0.7 μl Beta-Mercaptoethanol. These
samples were then vortexed for approximately one minute until well homogenized. After
homogenization, 100 μl sulfolane was added to the lysate and the samples were again vortexed
for approximately five seconds. It was noted that the samples became warm during this process.
Samples were then transferred to individual RNA-binding spin cups and centrifuged at 12,000 x
g for one minute. The filtrate was immediately discarded. Three hundred microliters of low-salt
wash buffer was then added to the spin column and centrifuged at 12,000 x g for an additional
minute with the filtrate again being discarded. The spin column was then centrifuged at 12,000 x
g for two minutes in order to completely dry the spin column. After patting the edges of the
column dry with a Kim-Wipe, 2.5 microliters RNase-Free DNase I was combined with 12.5
microliters DNase digestion buffer. The full 15 microliters of completed DNase solution was
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then added to the spin column and allowed to incubate in a 37°C bead-bath for 15 minutes. After
incubation, 300 microliters high-salt wash buffer was added to the column and centrifuged at
12,000 x g for one minute. The filtrate was again discarded and 300 microliters of low-salt wash
buffer was added to the column and centrifuged at 12,000 x g for one minute. After discarding
the filtrate, the column was spun for an additional three minutes to dry the column. After patting
the column dry with a kim-wipe, the cup was placed into a fresh two milliliter collection tube.
The provided elution buffer was warmed to 60°C, and 10 microliters of elution buffer was
quickly added to each column and allowed to sit for two minutes at room temperature. The
columns were then spun at 12,000 x g for five minutes and capped. A NanoDrop™ 2000 unit
(Thermo Scientific) was used to quantify the concentration of RNA within the resulting
solutions. NanoDrop™ analysis of the samples revealed a concentration of 10.3
nanograms/microliter for the human Jurkat cells and 5.1 nanograms/microliter for the human
CD8+ Anti-HPV cells.
2.2.3 Reverse Transcription
For both the Human Jurkat and Human CD8+ Anti-HPV cells reverse transcription of the
mRNA was performed. To do this, 20 nanograms of RNA (determined by nanodrop) was
combined with one microliter oligo (dT)20 (50 micromolar) and 1 microliter of a 10 mM dNTP
mix (10mM dATP, dGTP, dCTP, dTTP). The samples were then brought to 13 microliters using
PCR-grade water. These samples were then heated to 65°C for 5 minutes followed by immediate
incubation on ice for 1 minute.
Using the reagents provided with a superscript RT kit, four microliters 5x first strand
buffer, one microliter 0.1 M DTT, and one microliter Superscript III reverse transcriptase (200
units/microliter) were added to each sample. Additionally, 1 microliter RNaseIN™ was added to
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each sample to maximize cDNA yield. The samples were then mixed by gentle pipetting and
allowed to incubate at 50°C for one hour. Following this incubation, the reaction was inactivated
by heating at 70°C for 15 minutes.
To remove the mRNA strands from their cDNA counterparts, RNaseH (New England
Biolabs) was used. This was accomplished by adding 2.1 microliters RNaseH buffer and 1
microliter RNase H to each sample. These samples were then incubated at 37°C for 20 minutes
and immediately frozen and stored at -80°C.
2.2.4 PCR Amplification
In triplicate, both completed cDNA samples were combined in a PCR plate on ice with
the following reagents: five microliters SYBR™ Green Master Mix (Thermo Scientific), 0.5
microliters variable region primer mix, 0.5 microliters pCB1 primer, 1 microliter of respective
sample, and 3 microliters PCR grade water.
After the reagents were combined, the PCR reaction was carried out using the following
parameters:
Step
Denaturation
40 Cycles:
Denaturation
Annealing and
Extension
Fluorescence read

Temperature
94°C

Time
2 minutes

94°C

15 seconds

53°C

1 minute

A positive result would be indicated by fluorescence in the respective qPCR reactions following
amplification.
2.3 Results
None of the three samples for each of the two reactions showed any fluorescence during
the qPCR reaction. It should be noted that this experiment was repeated an additional time with
11

similar results, however in the second run of the experiment one of the wells for human Jurkat
cells began to show fluorescence after 19 cycles. Due to the fact that no other wells in the
triplicate reaction showed any fluorescence, it is assumed that this false positive was the result of
primer dimerization or contamination.
2.4 Discussion
It is uncertain why the 52-primer method was not successful. The theory behind the
method was sound and the protocols outlined were relatively standard (though applied in a
highly specialized manner). It is possible that the experiment failed due to human error (a primer
not being added properly), though it is also possible that the sheer number of primers used in this
experiment caused unanticipated interactions which prevented the reaction from working.
2.5 Notes
1. Bustin, S. (2002). Quantification of mRNA using real-time reverse transcription PCR
(RT-PCR): trends and problems. Journal of Molecular Endocrinology, 23–39.
https://doi.org/10.1677/jme.0.029002
2. Qiagen. “RNeasy Mini Handbook - (EN).” QIAGEN, Qiagen, 2019,
www.qiagen.com/us/resources/resourcedetail?id=14e7cf6e-521a-4cf7-8cbcbf9f6fa33e24&lang=en.
3. Robins et al. (2016) United Atates Patent No. US 2016/0319340 A1. Retrieved from
https://patentimages.storage.googleapis.com/6d/f5/15/429c32d67e56c0/US20160319340
A1.pdf
4. “Universal SYBR Green Quantitative PCR Protocol.” Millipore Sigma, Sigma Aldrich,
2019, www.sigmaaldrich.com/technical-documents/protocols/biology/sybr-greenqpcr.html.
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Chapter 3. C Tailing Method
3.1 Introduction
Due to the failures experienced with the 51-primer method discussed in the previous
chapter, it became necessary to explore alternative options for sequencing the TCRb gene. To
accomplish this, a spin on the traditional “C-tailing” method was used. Though the methods used
to achieve sequencing using C-tailing are relatively complex, the principle behind the method is
fairly simple. In order to elucidate the sequence of a given DNA strand, the DNA strand must
first be amplified using PCR. For a researcher to perform PCR, both a forward and reverse
primer are required. Creating a forward and reverse primer requires the researcher to know the
sequence of areas bracketing the DNA sequence of interest. In the case of mRNA for a gene like
TCRb, this is problematic as the sequence of interest is highly randomized. Fortunately, because
we are interested in the mRNA sequence of TCRb, we know that the 3’ end of the sequence of
interest will be the constant region of TCRb, which is relatively conserved. Because of this, a
primer for a sequence that is homologous for both constant region variants can be used. This
means that we are only left needing a reverse primer to sequence TCRb. Unfortunately, the 5’
end of the mRNA (and therefore the 3’ end of its cDNA after reverse transcription) for TCRb
begins with the hypervariable region of the gene. This means that under ordinary circumstances,
a single primer would be unable to provide sufficient specificity to allow for amplification of the
gene. This is remedied in the G-tailing method using an enzyme known as terminal
deoxynucleotidyl transferase (TdT). TdT adds random nucleotides to the 3’ end of any given
DNA sequence. To exploit this, we can allow TdT to perform its function on the cDNA of the
TCRb gene except do so in a solution that is devoid of all nucleotides except for cytosine. By
doing this, the cDNA has a poly-C repeat added to its 3’ end. This poly-C repeat allows us to
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design a reverse primer in the form of a Poly-G primer. Desoxyinosine residues are interspersed
within the sequence to lower the melting temperature of the primer and allow for successful PCR
amplification. Verification of a successful assay can be performed by qPCR where amplification
(indicated by fluorescence in the PCR reactions) is indicative that the Tailing reaction is
successful.
3.2 Methods
3.2.1 mRNA Isolation
RNA was isolated from Both Human Jurkat and Human CD8+ anti-HPV cells. This was
accomplished using an Absolutely RNA Nanoprep Kit (Agilent). Approximately 10,000 cells of
each sample were combined with 100 μl lysis buffer and 0.7 μl Beta-Mercaptoethanol. These
samples were then vortexed for approximately one minute until well homogenized. After
homogenization, 100 μl sulfolane was added to the lysate and the samples were again vortexed
for approximately five seconds. It was noted that the samples became warm during this process.
Samples were then transferred to individual RNA-binding spin cups and centrifuged at 12,000 x
g for one minute. The filtrate was immediately discarded. Three hundred microliters of low-salt
wash buffer was then added to the spin column and centrifuged at 12,000 x g for an additional
minute with the filtrate again being discarded. The spin column was then centrifuged at 12,000 x
g for two minutes in order to completely dry the spin column. After patting the edges of the
column dry with a Kim-Wipe, 2.5 microliters RNase-Free DNase I was combined with 12.5
microliters DNase digestion buffer. The full 15 microliters of completed DNase solution was
then added to the spin column and allowed to incubate in a 37°C bead-bath for 15 minutes. After
incubation, 300 microliters High-salt wash buffer was added to the column and centrifuged at
12,000 x g for one minute. The filtrate was again discarded and 300 microliters of low-salt wash
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buffer was added to the column and centrifuged at 12,000 x g for one minute. After discarding
the filtrate, the column was spun for an additional three minutes to dry the column. After patting
the column dry with a kim-wipe, the cup was placed into a fresh two milliliter collection tube.
After warming the provided elution buffer to 60°C, 10 microliters of elution buffer were quickly
added to the column and allowed to sit for two minutes at room temperature. The column was
then spun at 12,000 x g for five minutes and capped. A NanoDrop™ 2000 unit (Thermo
Scientific) was used to quantify the concentration of RNA within the resulting solution.
NanoDrop™ analysis of the samples revealed a concentration of 8.9 nanograms/microliter for
the human Jurkat cells and 7.8 nanograms/microliter for the human CD8+ Anti-HPV cells.
3.2.2 Reverse Transcription
For both the Human Jurkat and Human CD8+ Anti-HPV cells reverse transcription of the
mRNA was performed. To do this, 20 nanograms of RNA (determined by nanodrop) was
combined with one microliter oligo (dT)20 (50 micromolar) and 1 microliter of a 10 mM dNTP
mix (10mM dATP, dGTP, dCTP, dTTP). The samples were then brought to 13 microliters using
PCR-grade water. These samples were then heated to 65°C for 5 minutes followed by immediate
incubation on ice for 1 minute.
Using the reagents provided with a superscript RT kit, 4 microliters 5x first strand buffer,
one microliter 0.1 M DTT, and 1 microliter Superscript III reverse transcriptase (200
units/microliter) were added to each sample. Additionally, 1 microliter RNaseIN™ was added to
each sample to maximize cDNA yield. The samples were then mixed by gentle pipetting and
allowed to incubate at 50°C for one hour. Following this incubation, the reaction was inactivated
by heating at 70°C for 15 minutes.
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To remove the mRNA strands from their cDNA counterparts, RNaseH (New England
Biolabs) was used. This was accomplished by adding 2.1 microliters RNaseH buffer and 1
microliter RNase H to each sample. These samples were then incubated at 37°C for 20 minutes
and immediately frozen and stored at -80°C.
3.2.3 DNA Cleanup
DNA cleanup was performed using a GeneJET PCR purification kit (Thermo Scientific).
This step was necessary to remove any residual dNTPs which would be problematic for the
future TdT enzyme reaction. To do this, a 1:1 volume of binding buffer (approximately 25
microliters) was added to the previously created samples and thoroughly mixed. It was noted that
the samples were a bright yellow, indicating that the pH of the solution was correct for the assay.
The 50 microliters of this solution were then added to the GeneJet purification column and
centrifuged at 8,000 x g for 30 seconds, discarding the permeate. Seven hundred microliters
wash buffer was then added to each sample and centrifuged for 30 seconds, discarding the
permeate. The columns were then transferred to new microfuge tubes and centrifuged at 8,000 x
g for one minute to ensure that the columns were dry. The columns were again transferred to
fresh microfuge tubes and 20 microliters elution buffer was added to each column. After
centrifuging at 8,000 x g for a final minute, the samples were quantified via NanoDrop™ and
stored at -80°C for G-Tailing. NanoDrop™ assessment of the samples showed a concentration of
2.2 nanograms/microliter for the human Jurkat sample and 2.4 nanograms/microliter for the
human CD8+ anti-HPV cells.
3.2.4 Poly-C Tailing
Poly-C tailing was carried out using a TdT enzyme reaction kit purchased from New
England Biolabs. In clean microfuge tubes on ice, the following reagents were added in order: 5
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microliters 5x TDT buffer, 18.5 microliters of the clean cDNA product from previous steps, 0.5
microliters 10mM dCTP, and 1.5 microliters TdT enzyme. This reaction mix was then pipetted
gently to mix and gently spun to collect all reagents in the bottom of the microfuge tubes. The
reaction mixes were then incubated at 37°C for 15 minutes for the tailing reaction to proceed.
After the incubation, the samples were placed into a 70°C bead bath for 10 minutes to stop the
reaction by inactivating the enzyme.
3.2.5 Verification of Product Formation
The formation of properly formed product was verified using qPCR. Five microliters
SYBR™ Green PCR Master mix (Thermo Scientific) was combined on ice with 0.5 microliters
10mM pGI primer (primer which anneals to the poly-C sequence), 0.5 microliters 10mM pCB1
primer, two microliters of the tailed DNA product, and two microliters PCR grade water (The
sequence of both primers used in this reaction can be found in Appendix A). This was done in
triplicate for both samples. Thermocycling was then executed under the following parameters:
Step
Denaturation
40 Cycles:
Denaturation
Annealing and
Extension
Fluorescence read

Temperature
94°C

Time
2 minutes

94°C

15 seconds

53°C

1 minute

3.3 Results
All six samples that were run showed fluorescence by 30 cycles, indicating that the Ctailing reaction worked as intended. It should be noted that the product obtained from the PCR
reaction would not be ideal for sequencing as the specificity of amplification is quite low as a
result of effectively using only a single primer (due to the possibility of other unwanted genes
being amplified as well). Future reactions that required sequencing of the PCR product used a
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nested primer sequence in which two primers for the constant region were used to improve
specificity.
3.4 Notes
1. Bustin, S. (2002). Quantification of mRNA using real-time reverse transcription PCR
(RT-PCR): trends and problems. Journal of Molecular Endocrinology, 23–39.
https://doi.org/10.1677/jme.0.029002
2. Qiagen. “RNeasy Mini Handbook - (EN).” QIAGEN, Qiagen, 2019,
www.qiagen.com/us/resources/resourcedetail?id=14e7cf6e-521a-4cf7-8cbcbf9f6fa33e24&lang=en.
3. Thermo Scientific. “Product Information Thermo Scientific GeneJET Genomic DNA
Purification Kit.” Thermo Fisher Scientific, 2016.
4. “Universal SYBR Green Quantitative PCR Protocol.” Millipore Sigma, Sigma Aldrich,
2019, www.sigmaaldrich.com/technical-documents/protocols/biology/sybr-greenqpcr.html.
5. Wälchli, S., Løset, G., Kumari, S., Johansen, J., Yang, W., Sandliw, I., Olweus, J. 2011.
“A Practical Approach to T-Cell Receptor Cloning and Expression”. PLOS.
http://dx.doi.org/10.1371/journal.pone.0027930.
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Chapter 4. Synthesis of SiRNA Using a Whole Strand “Shotgun” Method
4.1 Introduction
One major issue with developing siRNA for a particular gene is the high level of
variability in siRNA effectiveness. Although a number of algorithms have been developed to
predict the effectiveness of a given siRNA, these formulas are far from infallible and very often
have no correlation with real-life applications.
The following methods were created as a highly reliable, low-cost technique to create
large quantities of SiRNA for a given TCRb gene. The general idea behind the method is as
follows:
•

First, the cDNA for the mRNA of the TCRb gene is amplified using conventional PCR as
well as the previously described C-Tailing method. A nested PCR reaction is used to
increase specificity (needed as the pGI primer is not specific to the cDNA of interest).

•

Next, a T7 promoter is hybridized to the cDNA samples using overhanging primers
incorporated into a PCR reaction

•

The dsDNA is melted and using the new T7 promoter attached to the cDNA templates,
transcription to RNA is carried out using T7 RNA polymerase.

•

The complimentary RNA strands created in the previous transcription reaction are
allowed to slowly cool and anneal to form dsRNA strands.

•

After cleaning the dsRNA using a column chromatography mini-prep, an RNase III
enzyme (DICER) is used to cleave the dsRNA strands into a series of siRNA molecules.

•

The siRNAs are then cleaned by glycogen/ethanol precipitation for use.

4.2 Methods
Note: all primer sequences can be found in appendix A.
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4.2.2 Nested PCR Reactions
The PCR reactions in this portion of the experiment were carried out using Titanium™
Taq DNA polymerase (Clontech). In two separate microfuge tubes on ice, the 15 microliters of
DNA created using the previously described C-tailing method for both human Jurkat and human
CD8+ anti-HPV cells were combined with 0.5 microliters pGI primer, 0.5 microliters pCB1
primer, one microliter dNTP mix, five microliters 10x taq buffer, one microliter taq polymerase,
and 27 microliters PCR grade water. After all reagents were added to their respective microfuge
tubes, the samples were mixed by gentle pipetting. Samples were then split into three separate
aliquots on a PCR plate (for a total of six total samples) and thermocycled under the following
parameters:
Step
Denaturation
20 Cycles:
Denaturation
Annealing
Extension
Fluorescence read (only
applicable to wells
using SYBR™ Green)

Temperature
94°C

Time
2 minutes

94°C
53°C
68°C

1 minute
1 minute
30 seconds

A parallel reaction using SYBR™ Green was carried out to verify that the PCR
amplification was successful. In duplicate, one microliter of the respective DNA samples were
combined with five microliters SYBR™ Green master mix as well as 0.5 microliters pGI primer
and 0.5 microliters pCB1 primer and three microliters PCR grade water. Fluorescence in these
samples using SYBR green after thermocycling could be used as a positive indication that the
reaction using Titanium™ Taq polymerase was successful.
After this first PCR reaction had completed, a second nested PCR reaction using a second primer
set was executed. Five microliters of DNA from each sample were placed into two separate
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microfuge tubes on ice. To these tubes, the following reagents were added: Five microliters 10x
taq buffer, 0.5 microliters pGI primer, 0.5 microliters pCB2 primer, one microliter dNTP mix,
one microliter 50x Titanium™ taq polymerase, and 37 microliters PCR grade water. After all
reagents were added to their respective microfuge tubes, the samples were mixed by gentle
pipetting. Samples were then split into three separate aliquots on a PCR plate (for a total of six
total samples) and thermocycled under the following parameters:
Step
Denaturation
20 Cycles:
Denaturation
Annealing
Extension
Fluorescence read (only
applicable to wells
using SYBR™ Green)

Temperature
94°C

Time
2 minutes

94°C
53°C
68°C

1 minute
1 minute
30 seconds

Again, a parallel reaction using SYBR™ Green was carried out to verify that the PCR
amplification was successful. In duplicate, one microliter of the respective DNA samples was
combined with five microliters SYBR™ Green master mix as well as 0.5 microliters pGI primer
and 0.5 microliters pCB2 primer and three microliters PCR grade water. Fluorescence in these
samples using SYBR green after thermocycling could be used as a positive indication that the
nested reaction using Titanium™ Taq polymerase was successful.
4.2.3 DNA Cleanup
DNA cleanup was performed using a GeneJET PCR purification kit (Thermo Scientific).
This step was necessary to remove any residual dNTPs which would be problematic for the
future TdT enzyme reaction. To do this, a 1:1 volume of binding buffer (approximately 25
microliters) was added to the previously created samples and thoroughly mixed. It was noted that
the samples were a bright yellow, indicating that the pH of the solution was correct for the assay.
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The 50 microliters of this solution were then added to the GeneJet purification column and
centrifuged at 8,000 x g for 30 seconds, discarding the permeate. Seven hundred microliters
wash buffer was then added to each sample and centrifuged for 30 seconds, discarding the
permeate. The columns were then transferred to new microfuge tubes and centrifuged at 8,000 x
g for one minute to ensure that the columns were dry. The columns were again transferred to
fresh microfuge tubes and 20 microliters elution buffer was added to each column. After
centrifuging at 8,000 x g for a final minute, the microfuge tubes were capped and stored at -80°C
for later steps.
4.2.4 T7 Promoter Hybridization
In two separate microfuge tubes on ice, five microliters of clean DNA from each sample
in the previous steps were combined with 0.5 microliters pGI+Promoter primer, 0.5 microliters
pCB2+Promoter primer, one microliter dNTP mix, five microliters 10x taq buffer, one microliter
taq polymerase, and 37 microliters PCR grade water. After all reagents were added to their
respective microfuge tubes, the samples were mixed by gentle pipetting. Samples were then split
into three separate aliquots on a PCR plate (for a total of six total samples) and thermocycled
under the following parameters:
Step
Denaturation
10 Cycles:
Denaturation
Annealing
Extension
Fluorescence read (only
applicable to wells
using SYBR™ Green)

Temperature
94°C

Time
2 minutes

94°C
53°C
68°C

1 minute
1 minute
30 seconds

A parallel reaction using SYBR™ Green was carried out to verify that the PCR
amplification was successful. In duplicate, one microliter of the respective DNA samples were
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combined with five microliters SYBR™ Green master mix as well as 0.5 microliters
pGI+promoter primer and 0.5 microliters pCB2+promoter primer and three microliters PCR
grade water. Fluorescence in these samples using SYBR green after thermocycling could be used
as a positive indication that the reaction using Titanium™ Taq polymerase was successful.
After this first PCR reaction had completed, a second nested PCR reaction using a second
primer set was executed. Five microliters of DNA from each sample were placed into two
separate microfuge tubes on ice. To these tubes, the following reagents were added: Five
microliters 10x taq buffer, one microliter T7 Promoter Primer, one microliter dNTP mix, one
microliter 50x Titanium™ taq polymerase, and 37 microliters PCR grade water. After all
reagents were added to their respective microfuge tubes, the samples were mixed by gentle
pipetting. Samples were then split into three separate aliquots on a PCR plate (for a total of six
total samples) and thermocycled under the following parameters:
Step
Denaturation
20 Cycles:
Denaturation
Annealing
Extension
Fluorescence read (only
applicable to wells
using SYBR™ Green)

Temperature
94°C

Time
2 minutes

94°C
53°C
68°C

1 minute
1 minute
30 seconds

Again, a parallel reaction using SYBR™ Green was carried out to verify that the PCR
amplification was successful. In duplicate, one microliter of the respective DNA samples was
combined with five microliters SYBR™ Green master mix as well as one microliter T7 Promoter
Primer and three microliters PCR grade water. Fluorescence in these samples using SYBR green
after thermocycling could be used as a positive indication that the nested reaction using
Titanium™ Taq polymerase was successful.
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4.2.5 DNA Cleanup
DNA cleanup was performed using a GeneJET PCR purification kit (Thermo Scientific).
This step was necessary to remove any residual dNTPs which would be problematic for the
future TdT enzyme reaction. To do this, a 1:1 volume of binding buffer (approximately 25
microliters) was added to the previously created samples and thoroughly mixed. It was noted that
the samples were a bright yellow, indicating that the pH of the solution was correct for the assay.
The 50 microliters of this solution were then added to the GeneJet purification column and
centrifuged at 8,000 x g for 30 seconds, discarding the permeate. Seven hundred microliters
wash buffer was then added to each sample and centrifuged for 30 seconds, discarding the
permeate. The columns were then transferred to new microfuge tubes and centrifuged at 8,000 x
g for one minute to ensure that the columns were dry. The columns were again transferred to
fresh microfuge tubes and 20 microliters elution buffer was added to each column. After
centrifuging at 8,000 x g for a final minute, the microfuge tubes were capped and stored at -80°C
for later steps.
4.2.6 Transcription
For both the human Jurkat and human CD8+ anti-HPV cell DNA product, transcription
was carried out using T7 RNA Polymerase (New England Biolabs). To transcribe the respective
DNA samples, the following were combined in a PCR plate on ice: Two microliters of the
respective DNA sample, four microliters PCR grade water, 10 microliters 2xNTP, two
microliters T7 reaction buffer, 0.5 microliters RNASEin (thermo scientific), and two microliters
T7 enzyme mix. It should be noted that there seemed to be a precipitate formed in the T7
reaction buffer that was re-dissolved by vortexing for several minutes. After mixing the reagents
by gentle pipetting, the samples were incubated in a PCR thermocycler unit for 2 hours at 37°C.
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4.2.7 Hybridization of ssRNA
After the incubation stage of the previous step, the PCR thermocycler was held at 75°C
for 5 minutes followed by a steady reduction to 4°C over a one hour period.
4.2.8 RNA Cleanup
RNA samples were cleaned using an RNeasy™ miniprep kit (Qiagen). To do this, each
sample had 20 microliters 70% EtOH added and mixed by pipetting. After this, the whole sample
was transferred to an RNeasy™ spin column and centrifuged at 8,000 x g for 15 seconds,
discarding the flow-through. Seven hundred microliters of reconstituted buffer RW1 was then
added, centrifuged for 15 seconds at 8,000 x g, and the flow-through again discarded. Five
hundred microliters buffer RPE was added to the spin columns and centrifuged at 8,000 x g for
15 seconds. A second 500 microliters buffer RPE was then added and centrifuged for two
minutes to ensure that the column was completely dry. Finally, the Rneasy spin column was
placed into a clean 1.5 microliter collection tube. Thirty microliters RNase-Free water warmed to
37°C (warmed to increase yield) was then added to the spin column membrane and spun at 8,000
x g for one minute. After this, siRNA synthesis was immediately proceeded to in order to
maximize yield (RNA has poor stability).
4.2.9 SiRNA Synthesis by RNase III
To create siRNA, Shortcut® RNase III (New England Biolabs) was used. The following
were combined on ice: The entire 30 microliters dsRNA from the previous step, 10 microliters
10x Shortcut Reaction Buffer, 10 microliters Shortcut RNase III, 10 microliters 10x MnCL2, and
40 microliters PCR grade water. This solution was then mixed by gentle pipetting and incubated
at 37°C for 20 minutes. The reaction was then halted by the addition of 10 microliters 10x EDTA
solution.
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4.2.10 SiRNA Precipitation
To precipitate the siRNAs, one-tenth volume 3M NaOAc, 2 microliters Rnase-free
Glycogen, and 360 microliters ice-cold 95% EtOH were added. This solution was then kept at 20°C for two hours. After incubation at -20°C, the samples were spun for 15 minutes at 12,000 x
g. At this point, a small pellet had formed at the bottom of each tube. The supernatant was
removed by gentle pipetting, taking care not to disturb the siRNA pellet. After wiping the top of
the microfuge tubes with a kim-wipe, an additional 300 microliters of ice-cold 80% ethanol
pipetted over the pellet and allowed to sit for 10 minutes at room temperature. The samples were
again centrifuged at 12,000 x g for 15 minutes and the supernatant removed by gentle pipetting.
The RNA was then resuspended in 30 microliters molecular biology grade water and stored at 80°C for future experimentation.
4.3 Results
All PCR samples ran successfully as indicated by fluorescence in the parallel qPCR
reactions using SYBR green.

4.4 Notes
1. Biolabs, New England. “T7 RNA Polymerase.” NEB, New England Biolabs, 2019,
www.neb.com/products/m0251-t7-rna-polymerase#Product%20Information.
2. Fedorov, Y., Anderson, E., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K.,
Leake, D., Marshall, W., Khvorova, A. 2006. “Odd-targeting Effects by siRNA can
Induce Toxic Phenotype”. RNA Society. 12:1188-1196.
3. Qiagen. “RNeasy Mini Handbook - (EN).” QIAGEN, Qiagen, 2019,
www.qiagen.com/us/resources/resourcedetail?id=14e7cf6e-521a-4cf7-8cbcbf9f6fa33e24&lang=en.
4. Thermo Scientific. “Product Information Thermo Scientific GeneJET Genomic DNA
Purification Kit.” Thermo Fisher Scientific, 2016.
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5. “Universal SYBR Green Quantitative PCR Protocol.” Millipore Sigma, Sigma Aldrich,
2019, www.sigmaaldrich.com/technical-documents/protocols/biology/sybr-greenqpcr.html.
6. Wälchli, S., Løset, G., Kumari, S., Johansen, J., Yang, W., Sandliw, I., Olweus, J. 2011.
“A Practical Approach to T-Cell Receptor Cloning and Expression”. PLOS.
http://dx.doi.org/10.1371/journal.pone.0027930.
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Chapter 5. Synthesis of SiRNA Designed with a Computational Method
Note: This section contains code snippets written in the visual basic language. The full source
code can be found in Appendix B.
5.1 Introduction
Although the previously described “shotgun” SiRNA synthesis method has many
benefits, including low chance of failure in RNA interference, it presents a number of potential
issues if intended for use as a therapeutic. Of these issues, the largest is likely the fact that with
so many created siRNA species, some siRNA species will exhibit off-targeting effects. These
effects can be avoided by creating specific siRNA species which have been blast searched
against the human genome to avoid siRNA species with high levels of homology to genes that
are unrelated to our target.
As previously mentioned, a major hurdle in creating siRNA for a particular gene is the
high level of variability in siRNA effectiveness. Fortunately, many algorithms have been
proposed based on meta data of successful siRNA species. Taken together, these algorithms can
predict the effectiveness of a given siRNA species with a fair degree of accuracy. Of the
prediction algorithms, one of the most popular and highly tested are the algorithms from
Reynalds et al 2004. Roughly, the algorithms put forward by Reynalds et al state the following:
•

An siRNA should have an overhang of two U residues on the 3’ end of both strands.

•

There should be an A residue in the 3 position

•

There should be an A residue in the 19th position

•

There should not be a G in position 13

•

There should be a U in position 10

•

There should not be a C or G in position 19
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•

There should not be a palindromic sequence of 4 or more bases

•

The GC content of the siRNA should fall between 30% and 52%

•

There should be at least one A or U residue in positions 15 through 19

•

There should not be a run of four consecutive A residues

•

There should not be a run of four consecutive U residues

After having established the rules for the design of siRNA in this experiment, it became
necessary to consider the method of synthesis used to create the siRNA. As the siRNA is
intended as a therapeutic, it would be ideal for whatever method is being used to be high
throughput, have a low turnaround time, and require minimal sophisticated equipment. Based on
these parameters, it was decided that a conventional oligo-based synthesis method be used (an
example of an oligo-based siRNA design kit being a Silencer™ siRNA construction kit (Thermo
scientific)). The general principle behind this type of method is that a DNA oligo for the
complimentary sequence of the siRNA intended to be synthesized is purchased. To this DNA
oligo, a T7 promoter is added. The compliment of this DNA sequence with a T7 promoter is also
purchased. Both DNA strands are then transcribed into complimentary single stranded RNAs and
allowed to anneal in such a way that they form completed siRNAs.
The methods required to both identify potential siRNA targeting sites as well as create
templates to synthesize said RNAs are both complicated and time consuming. Due to the size
and randomness of the TCRb gene, it is not viable to do most of these calculations by hand. To
alleviate this problem, a computer program which automates the siRNA targeting site
identification and subsequent DNA template design was created. This chapter outlines both the
design philosophy and code used to meet this goal.
5.1.1 Creation of Scoring System and Implementation of Algorithms
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For each discriminant put forward by Reynalds et al, a corresponding function was
created. Each of these functions receives a variable “siRNA” (as text) and returns a true or false
value as to whether or not the rules of the discriminant are met.
The following function checks position 3 of a given siRNA for the nucleotide “A”. If the
nucleotide is present, the Boolean value “True” (1) is returned. Otherwise, “False” (0) is
returned.
Function Discrim1(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
If GetChar(siRNA, 3) = "a" Or GetChar(siRNA, 3) = "A" Then
bool = True
End If
Return bool
End Function

This function looks for an “A” nucleotide in position 19 and returns the Boolean value “True” if
it is found or “False” if it is not.
Function Discrim2(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
If GetChar(siRNA, 19) = "a" Or GetChar(siRNA, 19) = "A" Then
bool = True
End If
Return bool
End Function
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In this function, “G” is checked for in position 13. If G is not found, “True” is returned (This is a
negative discriminant).
Function Discrim3(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
If Not GetChar(siRNA, 13) = "g" And Not GetChar(siRNA, 13) = "G" Then
bool = True
End If
Return bool
End Function

This function checks for a “U” residue in position 10. If the U residue is found, “True” is
returned.
Function Discrim4(ByVal siRNA As String) As Boolean

Dim bool As Boolean = False
If GetChar(siRNA, 10) = "u" Or GetChar(siRNA, 10) = "U" Then
bool = True
End If
Return bool
End Function
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The below function checks position 19 for the absence of both “C” and “G” residues. If neither
are present, “True” is returned (negative discriminant).
Function Discrim5(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
If Not GetChar(siRNA, 19) = "c" And Not GetChar(siRNA, 19) = "C" And Not
GetChar(siRNA, 19) = "g" And Not GetChar(siRNA, 19) = "G" Then
bool = True
End If
Return bool
End Function

The following function checks for even numbered palindromes of length 4 or greater. If a
Palindrome is found, “True” is returned.
Function Palindrome_check_4_units(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
Dim reverse_sequence As String = Strings.StrReverse(siRNA)
Dim count As Integer = 0
Dim forward As String = Nothing
Dim reverse As String = Nothing
Do While count < siRNA.Length - 4
forward = siRNA.Remove(0, count)
forward = siRNA.Substring(0, 4)
Dim count2 As Integer = 0

32

Do While count2 < siRNA.Length - 4
reverse = siRNA.Remove(0, count)
reverse = siRNA.Substring(0, 4)
If forward = reverse Then
bool = True
End If
count2 = count2 + 1
Loop
count = count + 1
Loop
Return bool
End Function

This function checks for odd numbered palindromes of length 5 or greater. If a palindrome is
found, “True” is returned.
Function Palindrome_check_5_units(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
Dim reverse_sequence As String = Strings.StrReverse(siRNA)
Dim count As Integer = 0
Dim forward As String = Nothing
Dim reverse As String = Nothing
Do While count < siRNA.Length - 5
forward = siRNA.Remove(0, count)
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forward = siRNA.Substring(0, 5)
Dim count2 As Integer = 0
Do While count2 < siRNA.Length - 5
reverse = siRNA.Remove(0, count)
reverse = siRNA.Substring(0, 5)
If forward = reverse Then
bool = True
End If
count2 = count2 + 1
Loop
count = count + 1
Loop
Return bool
End Function

This function Checks for the GC content of a given siRNA strand and returns a corresponding
value between 0 and 1.0.
Function Get_GC(ByVal siRNA As String, siRNA_length As Integer) As Double
Dim GC_content As Double = 0
Dim count As Integer = 0
Dim ATU_count As Integer = 0
Do While count < siRNA.Length
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If GetChar(siRNA, count + 1) = "a" Or GetChar(siRNA, count + 1) = "A" Or
GetChar(siRNA, count + 1) = "t" Or GetChar(siRNA, count + 1) = "T" Or GetChar(siRNA,
count + 1) = "u" Or GetChar(siRNA, count + 1) = "U" Then
ATU_count = ATU_count + 1
End If
count = count + 1
Loop
GC_content = 1 - (ATU_count / siRNA_length)
Return GC_content
End Function

The below function looks for A, U, or T residues between residues 15 and 19. The function
returns “True” if a residue is found.
Function AUT_in_15_through_19(ByVal sirna As String, sirna_Length As Integer) As Boolean
Dim bool As Boolean = False
Dim char15 As Char = GetChar(sirna, 15)
Dim char16 As Char = GetChar(sirna, 16)
Dim char17 As Char = GetChar(sirna, 17)
Dim char18 As Char = GetChar(sirna, 18)
Dim char19 As Char = GetChar(sirna, 19)
If char15 = "a" Or char15 = "A" Or char15 = "t" Or char15 = "T" Or char15 = "u" Or char15 =
"U" Then
bool = True
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End If
If char16 = "a" Or char16 = "A" Or char16 = "t" Or char16 = "T" Or char16 = "u" Or char16 =
"U" Then
bool = True
End If
If char17 = "a" Or char17 = "A" Or char17 = "t" Or char17 = "T" Or char17 = "u" Or char17 =
"U" Then
bool = True
End If
If char18 = "a" Or char18 = "A" Or char18 = "t" Or char18 = "T" Or char18 = "u" Or char18 =
"U" Then
bool = True
End If
If char19 = "a" Or char19 = "A" Or char19 = "t" Or char19 = "T" Or char19 = "u" Or char19 =
"U" Then
bool = True
End If
Return bool
End Function

This function checks for a leading “AA” sequence in the mRNA being targeted (The siRNA
compliment will be “UU”).
Function Check_for_AA(ByVal siRNA As String) As Boolean

36

Dim AA_Bool As Boolean = False
Dim Score As Integer = 0
If GetChar(siRNA, 1) = "A" Or GetChar(siRNA, 1) = "a" Then
Score = Score + 1
End If
If GetChar(siRNA, 2) = "A" Or GetChar(siRNA, 2) = "a" Then
Score = Score + 1
End If
If Score = 2 Then
AA_Bool = True
End If
Return AA_Bool
End Function

In this function, the algorithm checks for a running repeat of either four “A” or four “T”
residues. If this is found, “True” is returned.
Function Check_for_running_T_or_A(ByVal siRNA As String, sirna_length As Integer) As
Boolean
Dim Poly_T_A As Boolean = False
Dim count As Integer = 0
Dim tempstring As String = Nothing
Do While count < sirna_length - 4
tempstring = siRNA
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tempstring = tempstring.Remove(0, count) 'remove leading characters in temporary string
tempstring = tempstring.Substring(0, 4) ' trims temporary string to 4 characters
If tempstring = "aaaa" Or tempstring = "AAAA" Or tempstring = "TTTT" Or tempstring =
"tttt" Or tempstring = "UUUU" Or tempstring = "uuuu" Then
Poly_T_A = True
count = 9999999
'breaks loop
End If
count = count + 1
Loop
Return Poly_T_A
End Function

5.1.2 SiRNA Scoring
Scoring of siRNA candidates is based on the level of statistical significance assigned to
each individual discriminant by Reynalds et al. The respective “point value” of 7 of the 11
discriminants can be seen in the following list:
A in position 3
A in position 19
No G in position 13
U in position 10
No C or G in position 19
No palindromes of 4 or more
At least one A or U in 15 through 19
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16.8
22.1
14.1
30.6
25.6
10.1
16.9

Four of the eleven discriminants were considered absolutely necessary for an siRNA to be
successful (and were therefore not assigned a score). These four discriminants can be seen in the
t below:
No four consecutive A residues
No four consecutive U residues
The GC content must fall between 30% and 52%
There should not be a palindrome of 4 or more
bases
To apply the respective scores to each siRNA, the following code was used:
Do While count < codelength - SiRNA_Length
Dim GC_content As Double = Get_GC(DataArray(count), SiRNA_Length)
If Discrim1(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 16.8
End If
If Discrim2(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 22.1
End If
If Discrim3(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 14.1
End If
If Discrim4(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 30.6
End If
If Discrim5(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 25.6
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End If
If not Palindrome_check_4_units(DataArray(count)) And not
Palindrome_check_5_units(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 10.1
End If
If AUT_in_15_through_19(DataArray(count), DataArray(count).Length) Then
SiRNA_Score = SiRNA_Score + 16.9
End If
If Check_for_running_T_or_A(DataArray(count), DataArray(count).Length) Then
'Lowers score to a level where they will be ignored by future algorithms
SiRNA_Score = SiRNA_Score - 20000
End If
If Not Check_for_AA(DataArray(count)) Then
'Lowers score to a level where they will be ignored by future algorithms
SiRNA_Score = SiRNA_Score - 20000
End If
If Get_GC(DataArray(count), DataArray(count).Length) < 0.3 Or
Get_GC(DataArray(count), DataArray(count).Length) > 0.52 Then
'Lowers score to a level where they will be ignored by future algorithms
SiRNA_Score = SiRNA_Score - 20000
End If
ScoreArray(count) = SiRNA_Score
SiRNA_Score = 0
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count = count + 1
Loop

By assigning a score of “-20,000” to siRNAs that do not meet the necessary discriminants, these
siRNA are never returned to the user.
5.1.3 Identification of V, D, J, and C Regions
For the user’s information, an algorithm was designed to identify the V, D, J, and C
regions of a given RNA input. This was simply done by exploiting the fact that the V region is
typically 340 residues long, the D region is 16 residues long, and the J region is 50 residues long.
The following code was used to split the regions:
If Not CheckBox1.Checked Then
Do While TextBox1.Text.Length > count
If count <= 340 Then
RichTextBox2.Text = RichTextBox2.Text + GetChar(TextBox1.Text, count + 1)
End If
If count > 340 And count <= 356 Then
RichTextBox3.Text = RichTextBox3.Text + GetChar(TextBox1.Text, count + 1)
End If
If count > 356 And count <= 406 Then
RichTextBox4.Text = RichTextBox4.Text + GetChar(TextBox1.Text, count + 1)
End If
If count > 406 Then
RichTextBox5.Text = RichTextBox5.Text + GetChar(TextBox1.Text, count + 1)
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End If
count = count + 1
Loop
End If

5.1.4 Addition of T7 Promoter
As the goal of this program is to advise the user on what DNA oligoes are required to
create the siRNA of interest, an algorithm was used to systematically create complimentary
primer pairs with T7 promoters designed to synthesize complimentary RNA strands which will
create siRNA when hybridized. This is accomplished with the following code:
Do While count < codelength - SiRNA_Length
If ScoreArray(count) > 0 Then
'Displays siRNA candidate with respective score adjacent
RichTextBox1.Text = RichTextBox1.Text + DataArray(count) + " " +
ScoreArray(count).ToString + vbCrLf
'Displays siRNA candidate with the promoter sequence added
RichTextBox6.Text = RichTextBox6.Text + DataArray(count) + "CCTGTCTC" + "
" + ScoreArray(count).ToString + vbCrLf
'Removes leading AA to get compliment without overhang
DataArray(count).Remove(0, 2)
'Displays compliment and adds promoter sequence as well as AA overhang to the
compliment
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RichTextBox6.Text = RichTextBox6.Text + "AA" +
Convert_to_Compliment(DataArray(count)) + "CCTGTCTC" + vbCrLf + vbCrLf
End If
count = count + 1
Loop

5.1.5 User Interface
The user interface for this program was designed to both be all-inclusive and easily
accessible. The two primary user inputs are the TCRb sequence as well as the desired siRNA
length (with 23 as the optimal default). Additionally, the user may specify if their input only
contains the CDR3 region, is the RNA compliment, or is the cDNA of the TCRb sequence. The
user may also specify if they would like a number of residues trimmed from the front or back of
the TCRb sequence (as interior sequences tend to be more favorable for inhibition by siRNA).
The code for all of these user inputs (all of which are code-commented) can be found in
appendix B. The user interface before having received input can be seen below:
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Figure 5.1. TCRb siRNA Solver user interface
The user interface after having received a TCRb sequence can be seen here:
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Figure 5.2. TCRb siRNA Solver user interface after having run data
5.2 Conclusion
The described program was tested for accuracy against hand calculations for the same
TCRb sequences. After extensive debugging, it was found that the calculations were identical in
all cases. Additionally, the calculations done by the program are not only far less time
consuming but are also far less error prone (especially given the complexity required to make
this type of calculation).
5.3 Notes
Fedorov, Y., Anderson, E., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake,
D., Marshall, W., Khvorova, A. 2006. “Odd-targeting Effects by siRNA can Induce Toxic
Phenotype”. RNA Society. 12:1188-1196.
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Chapter 6. Testing of SiRNA on an Ex Vivo Immune Cell Model and
Conclusions
6.1 Introduction
To test the efficacy of the various siRNA formulations previously described, qPCR was
utilized. The qPCR experiment looked at the ability of each siRNA formulation to knock down
three genes: TCRb, CD3, and CD137. In theory, TCRb should be directly knocked down as a
result of the siRNA causing the TCRb mRNA to be degraded directly. CD3 is a co-receptor
which conjugates to a completed T cell receptor upon its migration to the cell surface. A
feedback loop decreases the level of CD3 in the absence of TCRb expression due to translated
CD3 receptors being unable to migrate to the T cell surface. The final gene, CD137, is expressed
by activated T cells. T cells which do not express their receptor complexes are unable to undergo
activation and are therefore incapable of expressing CD137 at normal levels. β-actin was also
measured to normalize the genes of interest.
In addition to testing for the expression of the aforementioned genes, cell viability was
also tested. This is important as the intended mechanism of the siRNA is to prevent the cells
from expressing their receptors while leaving their viability unaffected. Although T cells which
do not express their receptors should be unable to proliferate at any significant level, the lack of
receptors should not be directly toxic to the cells. Cell viability analysis was done both by MTS
assay as well as direct count with trypan blue.
An important consideration for this type of therapy is that the siRNA synthesized for one
particular T cell line should not be effective against other cell lines. This is important because the
major benefit of using siRNA synthesized with the methods previously described is the isolation
of the effect to only “pathogenic” T cell lines (as opposed to all cell lines being affected with a
therapy such as corticosteroids). Additionally, negative controls were used to ensure any effects
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witnessed were a result of the siRNA cocktails and not the vectors being used to deliver the
therapies (lipofectamine™ (Thermo Scientific)).
6.2 Methods
6.2.1 SiRNA Synthesis Using a “Shotgun” Method
For both human Jurkat, and human CD8+ anti-HPV cells, siRNA was synthesized using
the previously described “shotgun” method. These siRNAs were frozen and stored at -80⁰C for
further experimentation.
6.2.2 SiRNA Synthesis Using a Computational Method
For both human Jurkat, and human CD8+ anti-HPV cells, the mRNA sequence of their
respective TCRb genes were sequenced. After the sequence had been obtained for both samples,
the three highest scoring primer pairs were determined using the previously created siRNA
solver program. These primer pairs were purchased for use in the synthesis of siRNA for the
respective TCRb genes. The six primer pairs used for siRNA synthesis and their corresponding
scores can be found in the following table.
Table 6.1. List of Oligos and Corresponding Scores.
Sample
Human
Jurkat

Human
CD8+
antiHPV

Oligo one
AAGAAUCGAUUGUUGGGCAUACCCC
TGTCTC
AAACCAGGACCCCAGAAGAGAAUCC
TGTCTC
AAAGGGUUACAUGACCCGAAAUUCC
TGTCTC

Oligo two
AAGGUAUGCCCAACAAUCGAUUCCC
TGTCTC
AAAUUCUCUUCUGGGGUCCUGGUCC
TGTCTC
AAAAUUUCGGGUCAUGUAACCCUCC
TGTCTC

AAGCUUAGCUCUAAGGUGUCAGGCC
TGTCTC
AAGAUUAUCAUGUCCAGAAAUUGCC
TGTCTC
AAGCCUGGAAACCAUGCUAAGCUCC
TGTCTC

AACCUGACACCUUAGAGCUAAGCCC
TGTCTC
AACAAUUUCUGGACAUGAUAAUCCC
TGTCTC
AAAGCUUAGCAUGGUUUCCAGGCCC
TGTCTC

Score
110

After the primers had been obtained, synthesis of siRNA was carried out using a
Silencer™ siRNA construction kit (Thermo Scientific). To do this, template oligonucleotides
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96
82

88
79
79

were suspended to a concentration of 100 micromolar in nuclease free water. The templates were
then hybridized to the T7 promoter primer provided with the Silencer™ SiRNA construction kit
by mixing two microliters of each one of the six oligonucleotides with six microliters
hybridization buffer as well as two microliters T7 promoter primer. The mixture was then heated
to 70 ⁰C for 5 minutes and subsequently allowed to sit at room temperature for an additional 5
minutes. After hybridization with the T7 primer, the gap left behind was filled in with Klenow
DNA polymerase. This was done by adding the following directly to each hybridization mixture:
two microliters 10x Klenow reaction buffer, two microliters dNTP mid, four microliters
nuclease-free water, and two microliters of Exo-Klenow enzyme. This mixture was mixed by
slow pipetting and transferred to a 37⁰C bead-bath for 30 minutes.
To assemble the transcription reaction, two microliters of each of the previous samples
combined in an ependorf tube on ice with the following: four microliters nuclease-free water, 10
microliters NTP mix, two microliters 10x T7 reaction buffer, and two microliters T7 enzyme
mix. It should be noted that a considerable degree of precipitate had formed on top of the T7
reaction buffer which required vertexing to resuspend. All components were mixed by gentle
pipetting and the reaction was incubated in a 37⁰C bead-bath for two hours. After the initial
incubation, each of the primer pairs were combined (leaving six total samples) and allowed to
continue incubation at 37⁰C overnight (12 hours).
After the samples had been incubated overnight, each ~40 microliter sample had the
following added: six microliters digestion buffer, 2.5 microliters DNase, three microliters RNase,
and 48.5 microliters nuclease-free water. This reaction was mixed by gentle pipetting and
allowed to incubate for two hours at 37⁰C. After preparing both the siRNA biding buffer and
siRNA wash buffer as described by the manufacturer, 400 microliters of siRNA binding buffer
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was added to each sample and allowed to incubate for 5 minutes at room temperature. Nucleasefree water was then heated to 75⁰C for later use. Six siRNA filter cartridges were placed into
2mL collection tubes and 100 microliters siRNA wash buffer was added to each of these
cartridges. Each siRNA sample with binding buffer was added to separate tubes and centrifuged
at 10,000 x g for one minute. The flow-through of each sample was discarded and the collection
tubes were replaced. Each cartridge was then washed twice with 500 microliters siRNA wash
buffer by spinning the columns at 10,000 x G for one minute with the flow-through being
discarded. Finally, siRNA was eluted from each cartridge by adding 100 microliters nucleasefree water heated to 75⁰C and centrifuging for 2 minutes at 12,000 x g. The siRNA created were
stored at -80⁰C for later use.
6.2.3 SiRNA Lipofection
The eight separate siRNA samples created from previous steps were lipofected using
Lipofectamine ™ RNAiMax lipofection reagent (Thermo Scientific). For each sample, fifty
microliters Opti-MEM™ (Thermo Scientific) medium was combined with three microliters
Lipofectamine™ RNAiMAX reagent. For each sample, in a separate tube, 50 microliters OptiMEM™ medium was combined with 10 picomoles siRNA (concentration determined by
nanodrop). The diluted lipofectamine and diluted siRNA for each respective sample were then
combined and allowed to incubate at room temperature for 5 minutes.
6.2.4 Treatment of Cell Lines with SiRNA
After allowing both the human Jurkat and human CD8+ anti-HPV cells to grow for 48
hours, Cells were seeded at 200,000 cells per 190 microliters of media in a 96 well plate in
triplicate. To each of these wells, ten microliters of the respective lipofected siRNA mix was
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added (for an addition of one picomol siRNA per well). Samples were then allowed to incubate
for 24 hours at 37⁰C and analyzed after incubation.
6.2.5 qPCR
One hundred microliters of each sample (approximately 100,000 cells) were removed
from each well and processed through an RNeasy mini kit (Qiagen). Samples were spun down
and their supernatant removed by gentle pipetting. The cell pellets that formed were resuspended
in 350 microliters buffer RLT. These cells were then vortexed to homogenize, and added to
RNeasy spin columns placed in collection tubes. These samples were then spun at 8,000 x g for
15 seconds and their flow-through discarded. After this, 700 microliters buffer RW1 was added
to each sample, centrifuged at 8,000 x g for 15 seconds, and the flow-through again discarded.
Two separate 500 microliter aliquots of buffer RPE were then added to each sample, centrifuged
at 8,000 x g for 15 seconds, and the flow through discarded. After having placed each sample in
a fresh collection tube, the RNA was eluted by placing 30 microliters of RNase-free water to
each column and centrifuging at 8,000 x g for a final minute.
After each samples RNA had been isolated, qPCR was performed using a SuperScript™
IV One-Step RT-PCR system (Invitrogen). The three genes being tested for each sample were
TCRb, CD3, CD137, and β-actin (normalization). These samples used primers TCRb-f, TCRb-r,
CD3-f, CD3-r, CD137-f, CD137-r, β-actin-f, and β-actin-r respectively. The sequences for these
primers can be found in appendix a. To execute qPCR, 25 microliters 2x Platinum™ RT-PCR
Master Mix was combined with two microliters of the previously created RNA samples, 2.5
microliters of each sample’s respective primers at 10 micromolar (5 microliters primer per
sample), 0.5 microliters superscript IV enzyme mix, and 17.5 microliters nuclease-free water.
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These samples were then mixed by gentle pipetting and run under the following thermo-cycler
parameters:
Step
Reverse Transcription
Denaturation
Amplification
(40 cycles)
Final Extension

Temperature
55C
98C
98C
58C
72C
72C

Time
1 minutes
2 minutes
10 seconds
10 seconds
1 minute
5 minutes

After thermocycling, samples had their CT values normalized by their respective β-actin
expression and were compared by the ΔΔCT method. All qPCR was performed in triplicate for
each of the three replicates for each sample (for a total of 9 replicates for each treatment group).
6.2.6 Cell Viability by Trypan Blue Count
To quantify cell viability by direct count, 10 microliters of each sample were removed
from each well and placed into separate microfuge tubes. To each tube, an equal volume of
trypan blue was added. These cells were then counted under a microscope and their values
compared to one another. This assay was performed for each of the triplicate for all samples.
6.2.7 Cell Viability by MTS
To quantify cell viability, MTS reagent (Abcam) was obtained. The remaining 90
microliters microliters (~90,000 cells) of each well was combined with 10 microliters MTS
reagent and incubated for 4 hours at 37⁰C. After brief agitation, the plate was analyzed
spectrophotometrically at an absorbance value of 490 nm.
6.3 Results
6.3.1 qPCR Results
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Gene expression for all samples were quantified relative to the negative control. The
results for each of the three genes for both human Jurkat and human CD8+ anti-HPV cells can be
seen in the graphs below:

qPCR of TCRb for Human Jurkat Cells
"Shotgun" siRNA cocktail (human CD8+
anti-HSV)
"Shotgun" siRNA cocktail
Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1

Negative Control
-0.2

0

0.2

0.4

0.6

0.8

1

1.2

Figure 6.1. qPCR results for TCRb on human Jurkat cells.

qPCR of TCRb for Human CD8+ anti-HPV Cells
"Shotgun" siRNA cocktail (human
Jurkat)
"Shotgun" siRNA cocktail
Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1
Negative Control
0

0.2

0.4

0.6

0.8

1

Figure 6.2. qPCR of TCRb for human CD8+ anti-HPV cells
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1.2

qPCR of CD3 for Human Jurkat Cells
"Shotgun" siRNA cocktail (human CD8+
anti-HSV)
"Shotgun" siRNA cocktail
Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1
Negative Control
-0.2
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0.4

0.6

0.8
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Figure 6.3. qPCR results for CD3 on human Jurkat cells.

qPCR of CD3 for Human CD8+ anti-HPV Cells
"Shotgun" siRNA cocktail (human
Jurkat)
"Shotgun" siRNA cocktail
Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1
Negative Control
0

0.2

0.4

0.6

0.8

1

Figure 6.4. qPCR of CD3 for human CD8+ anti-HPV cells
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qPCR of CD134 for Human Jurkat Cells
"Shotgun" siRNA cocktail (human CD8+
anti-HSV)
"Shotgun" siRNA cocktail
Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1
Negative Control
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Figure 6.5. qPCR results for CD137 on human Jurkat cells.

qPCR of CD137 for Human CD8+ anti-HPV Cells
"Shotgun" siRNA cocktail (human
Jurkat)
"Shotgun" siRNA cocktail
Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1
Negative Control
0
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0.4

0.6

0.8

1

1.2

Figure 6.6. qPCR of CD137 for human CD8+ anti-HPV cells

6.3.2 Cell Viability by MTS
Cell viability via MTS was calculated relative to the negative control. The results for the
human Jurkat cells can be seen in the graph below:
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Cell viability by MTS assay for Human Jurkat Cells
"Shotgun" siRNA cocktail (human CD8+
anti-HSV)
"Shotgun" siRNA cocktail
Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1
Negative Control
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0.6

0.8

1
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1.4

Figure 6.7. Cell viability count results utilizing MTS on human Jurkat cells

All samples demonstrated no significant difference from the control with a P value > 0.05 for all
comparisons.
The results for the human CD8+ anti-HPV cells can be seen in the below graph:

Cell viability by MTS assay for Human CD8+ AntiHPV Cells
"Shotgun" siRNA cocktail (human…
"Shotgun" siRNA cocktail

Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1
Negative Control
0

0.2

0.4

0.6

0.8

1

1.2

1.4

Figure 6.8. Cell viability results utilizing MTS on human CD8+ anti-HPV cells
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All samples demonstrated no significant difference from the control with a P value > 0.05 for all
comparisons.
6.3.3 Cell Viability by Trypan Blue
Cell viability via Trypan blue was quantified relative to the negative control. The results
for human Jurkat cells can be seen below:

Cell viability by Trypan Blue Count for Human
Jurkat Cells
"Shotgun" siRNA cocktail (human…
"Shotgun" siRNA cocktail
Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1
Negative Control
0

0.2

0.4

0.6

0.8

1

1.2

Figure 6.9. Cell viability count results utilizing trypan blue on human Jurkat cells

All samples demonstrated no significant difference from the control with a P value > 0.05 for all
comparisons.
Results for the human CD8+ anti-HPV cells can be seen here:
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Cell viability by Trypan Blue Count for Human
CD8+ Anti-HPV Cells
"Shotgun" siRNA cocktail (human…
"Shotgun" siRNA cocktail
Computationally derived siRNA 3
Computationally derived siRNA 2
Computationally derived siRNA 1
Negative Control
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Figure 6.10. Cell viability count results utilizing trypan blue on human CD8+ anti-HPV cells

All samples with the exception of the computationally derived siRNA #1 did not vary
significantly from the control with a P value > 0.05.
6.4 Discussion
These results demonstrated a high level of effectiveness for all siRNA species targeting
TCRb. Additionally, cocktails for human Jurkat used to treat human CD8+ anti-HPV cells had a
minimal effect on gene expression. The reverse observation was the same, with siRNA
synthesized for human CD8+ anti-HPV cells having minimal effect on human Jurkat cells. These
observations taken together not only demonstrate the potency of siRNA synthesized with the
methods outlined, but the high level of targeting specificity was demonstrated as well. It should
be noted that only a single siRNA species seemed to have an impact on cell viability, meaning
that the siRNAs elicit their effect on cells by inhibiting gene expression and not by a directly
toxic mechanism. Though all siRNA were effective, siRNA synthesized with the previously
described “shotgun” method demonstrated the highest level of effectiveness at gene suppression
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for all genes tested. This is likely because of the large array of siRNA species created when
making siRNA in this manner.
T cells that are incapable of expressing TCRb are physiologically unable to elicit an
inflammatory response. If a T cell cannot elicit an inflammatory response, it is unable to
proliferate. Given the high level of effectiveness for siRNAs which have been prudently
synthesized to knock down the expression of TCRb, these siRNA species are potentially a
potent, novel means of therapy for the treatment of autoimmunity.
6.5 Notes
1. Abcam, “MTS Cell Proliferation Assay Kit (Colorimetric).” MTS Cell Proliferation Assay
Protocol, Abcam, 2019,
www.abcam.com/ps/products/197/ab197010/documents/ab197010%20MTS%20Cell%20Pro
liferation%20Colorimetric%20Assay%20Kit%20Protocol%20v3b%20(website).pdf.
2. Biolabs, New England. “ShortCut RNase III Digestion Protocol (M0245).” NEB, New
England Biolabs, 2019, www.neb.com/protocols/0001/01/01/shortcut-rnase-iii-digestionprotocol-m0245.
3. Lovatt, A., et al., Validation of Quantitative PCR Assays, BioPharm., March 2002, p.22-32.
4. Oha, Y., Parkbm T. 2009. “siRNA delivery systems for cancer treatment”. Advanced Drug
Delivery Reviews. 61(10): 850-862.
5. Pauley, K., Cha, S. 2013. “RNAi Therapeutics in Autoimmune Disease”. Pharmaceuticals
(Basel). 6(3): 287-294.
6. “Universal SYBR Green Quantitative PCR Protocol.” Millipore Sigma, Sigma Aldrich, 2019,
www.sigmaaldrich.com/technical-documents/protocols/biology/sybr-green-qpcr.html.
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Appendix A. Primer Sequences
Oligo Name
TRB2V10-1
TRB2V10-2
TRB2V10-3
TRB2V6-2/3
TRB2V6-8
TRB2V6-9
TRB2V6-5
TRB2V6-6
TRB2V6-7
TRB2V6-1
TRB2V6-4
TRB2V24-1
TRB2V25-1
TRB2V27
TRB2V26
TRB2V28
TRB2V19
TRB2V4-1
TRB2V4-2/3
TRB2V2P
TRB2V3-1
TRB2V3-2
TRB2V16
TRB2V23-1
TRB2V18
TRB2V17
TRB2V14
TRB2V2
TRB2V12-1
TRB2V12-2
TRB2V12-3/4
TRB2V12-5
TRB2V7-9
TRB2V7-8
TRB2V7-4
TRB2V7-6/7
TRB2V7-2
TRB2V7-3

Oligo Sequence
AACAAAGGAGAAGTCTCAGATGGCTACAG
GATAAAGGAGAAGTCCCCGATGGCTATGT
GACAAAGGAGAAGTCTCAGATGGCTATAG
GCCAAAGGAGAGGTCCCTGATGGCTACAA
CTCTAGATTAAACACAGAGGATTTCCCAC
AAGGAGAAGTCCCCGATGGCTACAATGTA
AAGGAGAAGTCCCCAATGGCTACAATGTC
GACAAAGGAGAAGTCCCGAATGGCTACAAC
GTTCCCAATGGCTACAATGTCTCCAGATC
GTCCCCAATGGCTACAATGTCTCCAGATT
GTCCCTGATGGTTATAGTGTCTCCAGAGC
ATCTCTGATGGATACAGTGTCTCTCGACA
TTTCCTCTGAGTCAACAGTCTCCAGAATA
TCCTGAAGGGTACAAAGTCTCTCGAAAAG
CTCTGAGAGGTATCATGTTTCTTGAAATA
TCCTGAGGGGTACAGTGTCTCTAGAGAGA
TATAGCTGAAGGGTACAGCGTCTCTCGGG
CTGAATGCCCCAACAGCTCTCTCTTAAAC
CTGAATGCCCCAACAGCTCTCACTTATTC
CCTGAATGCCCTGACAGCTCTCGCTTATA
CCTAAATCTCCAGACAAAGCTCACTTAAA
CTCACCTGACTCTCCAGACAAAGCTCAT
TTCAGCTAAGTGCCTCCCAAATTCACCCT
GATTCTCATCTCAATGCCCCAAGAACGC
ATTTTCTGCTGAATTTCCCAAAGAGGGCC
ATTCACAGCTGAAAGACCTAACGGAACGT
TCTTAGCTGAAAGGACTGGAGGGACGTAT
TTCGATGATCAATTCTCAGTTGAAAGGCC
TTGATTCTCAGCACAGATGCCTGATGT
GCGATTCTCAGCTGAGAGGCCTGATGG
TCGATICICAGCTAAGATGCCIAATGC
TTCTCAGCAGAGATGCCTGATGCAACTTTA
GGTTCTCTGCAGAGAGGCCTAAGGGATCT
GCTGCCCAGTGATCGCTTCTTTGCAGAAA
GGCGGCCCAGTGGTCGGTTCTCTGCAGAG
ATGATCGGTTCTCTGCAGAGAGGCCTGAGG
AGTGATCGCTTCTCTGCAGAGAGGACTGG
GGCTGCCCAACGATCGGTTCTTTGCAGT
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TRB2V7-1
TRB2Vll- 123
TRB2V13
TRB2V5-1
TRB2V5-3
TRB2V5-4
TRB2V5-8
TRB2V5-5
TRB2V5-6
TRB2V9
TRB2V15
TRB2V30
TRB2V20-1
TRB2V29-1
pCb1
pCb2
pGI
Human Jurkat 1-1
Human Jurkat 1-2
Human Jurkat 2-1
Human Jurkat 2-2
Human Jurkat 3-1
Human Jurkat 3-2
Human CD8+ Anti-HPV 1-1
Human CD8+ Anti-HPV 1-2
Human CD8+ Anti-HPV 2-1
Human CD8+ Anti-HPV 2-2
Human CD8+ Anti-HPV 3-1
Human CD8+ Anti-HPV 3-2

TCCCCGTGATCGGTTCTCTGCACAGAGGT
CTAAGGATCGATTTTCTGCAGAGAGGCTC
CTGATCGATTCTCAGCTCAACAGTTCAGT
TGGTCGATTCTCAGGGCGCCAGTTCTCTA
TAATCGATTCTCAGGGCGCCAGTTCCATG
TCCTAGATTCTCAGGTCTCCAGTTCCCTA
GGAAACTTCCCTCCTAGATTTTCAGGTCG
AAGAGGAAACTTCCCTGATCGATTCTCAGC
GGCAACTTCCCTGATCGATTCTCAGGTCA
GTTCCCTGACTTGCACTCTGAACTAAAC
GCCGAACACTTCTTTCTGCTTTCTTGAC
GACCCCAGGACCGGCAGTTCATCCTGAGT
ATGCAAGCCTGACCTTGTCCACTCTGACA
CATCAGCCGCCCAAACCTAACATTCTCAA
TTCACCCACCAGCTCAGCTCC
ATACGCGTAGATCTCTGCTTCTGATGGC
CACCGGGIIGGGIIGGGII
AAGAAUCGAUUGUUGGGCAUACCCCTGTCTC
AAGGUAUGCCCAACAAUCGAUUCCCTGTCTC
AAACCAGGACCCCAGAAGAGAAUCCTGTCTC
AAAUUCUCUUCUGGGGUCCUGGUCCTGTCTC
AAAGGGUUACAUGACCCGAAAUUCCTGTCTC
AAAAUUUCGGGUCAUGUAACCCUCCTGTCTC
AAGCUUAGCUCUAAGGUGUCAGGCCTGTCTC
AACCUGACACCUUAGAGCUAAGCCCTGTCTC
AAGAUUAUCAUGUCCAGAAAUUGCCTGTCTC
AACAAUUUCUGGACAUGAUAAUCCCTGTCTC
AAGCCUGGAAACCAUGCUAAGCUCCTGTCTC
AAAGCUUAGCAUGGUUUCCAGGCCCTGTCTC
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Appendix B. TCRb siRNA Solver Source Code

Figure 8.1. User Interface
8.1 User Interface Source Code
_ Partial Class Form1 Inherits System.Windows.Forms.Form
'Form overrides dispose to clean up the component list.
<System.Diagnostics.DebuggerNonUserCode()> _
Protected Overrides Sub Dispose(ByVal disposing As Boolean)
Try
If disposing AndAlso components IsNot Nothing Then
components.Dispose()
End If
Finally
MyBase.Dispose(disposing)
End Try
End Sub
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'Required by the Windows Form Designer
Private components As System.ComponentModel.IContainer
'NOTE: The following procedure is required by the Windows Form Designer
'It can be modified using the Windows Form Designer.
'Do not modify it using the code editor.
<System.Diagnostics.DebuggerStepThrough()> _
Private Sub InitializeComponent()
Me.Button1 = New System.Windows.Forms.Button()
Me.TextBox1 = New System.Windows.Forms.TextBox()
Me.TextBox2 = New System.Windows.Forms.TextBox()
Me.RichTextBox1 = New System.Windows.Forms.RichTextBox()
Me.CheckBox1 = New System.Windows.Forms.CheckBox()
Me.CheckBox2 = New System.Windows.Forms.CheckBox()
Me.RichTextBox2 = New System.Windows.Forms.RichTextBox()
Me.CheckBox3 = New System.Windows.Forms.CheckBox()
Me.TextBox3 = New System.Windows.Forms.TextBox()
Me.Label1 = New System.Windows.Forms.Label()
Me.Label2 = New System.Windows.Forms.Label()
Me.Label3 = New System.Windows.Forms.Label()
Me.TextBox4 = New System.Windows.Forms.TextBox()
Me.RichTextBox3 = New System.Windows.Forms.RichTextBox()
Me.RichTextBox4 = New System.Windows.Forms.RichTextBox()
Me.RichTextBox5 = New System.Windows.Forms.RichTextBox()
Me.Label4 = New System.Windows.Forms.Label()
Me.Label5 = New System.Windows.Forms.Label()
Me.Label6 = New System.Windows.Forms.Label()
Me.RichTextBox6 = New System.Windows.Forms.RichTextBox()
Me.Label8 = New System.Windows.Forms.Label()
Me.Label9 = New System.Windows.Forms.Label()
Me.Label10 = New System.Windows.Forms.Label()
Me.Label7 = New System.Windows.Forms.Label()
Me.Label11 = New System.Windows.Forms.Label()
Me.SuspendLayout()
'
'Button1
'
Me.Button1.Location = New System.Drawing.Point(237, 213)
Me.Button1.Name = "Button1"
Me.Button1.Size = New System.Drawing.Size(75, 23)
Me.Button1.TabIndex = 0
Me.Button1.Text = "Run"
Me.Button1.UseVisualStyleBackColor = True
'
'TextBox1
'
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Me.TextBox1.Location = New System.Drawing.Point(12, 35)
Me.TextBox1.Name = "TextBox1"
Me.TextBox1.Size = New System.Drawing.Size(300, 20)
Me.TextBox1.TabIndex = 2
'
'TextBox2
'
Me.TextBox2.Location = New System.Drawing.Point(12, 77)
Me.TextBox2.Name = "TextBox2"
Me.TextBox2.Size = New System.Drawing.Size(100, 20)
Me.TextBox2.TabIndex = 4
Me.TextBox2.Text = "23"
'
'RichTextBox1
'
Me.RichTextBox1.Location = New System.Drawing.Point(338, 34)
Me.RichTextBox1.Name = "RichTextBox1"
Me.RichTextBox1.Size = New System.Drawing.Size(234, 620)
Me.RichTextBox1.TabIndex = 5
Me.RichTextBox1.Text = ""
'
'CheckBox1
'
Me.CheckBox1.AutoSize = True
Me.CheckBox1.Location = New System.Drawing.Point(13, 104)
Me.CheckBox1.Name = "CheckBox1"
Me.CheckBox1.Size = New System.Drawing.Size(114, 17)
Me.CheckBox1.TabIndex = 6
Me.CheckBox1.Text = "Input is CDR3 only"
Me.CheckBox1.UseVisualStyleBackColor = True
'
'CheckBox2
'
Me.CheckBox2.AutoSize = True
Me.CheckBox2.Location = New System.Drawing.Point(13, 128)
Me.CheckBox2.Name = "CheckBox2"
Me.CheckBox2.Size = New System.Drawing.Size(86, 17)
Me.CheckBox2.TabIndex = 7
Me.CheckBox2.Text = "Input is DNA"
Me.CheckBox2.UseVisualStyleBackColor = True
'
'RichTextBox2
'
Me.RichTextBox2.Location = New System.Drawing.Point(12, 275)
Me.RichTextBox2.Name = "RichTextBox2"
Me.RichTextBox2.Size = New System.Drawing.Size(300, 80)
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Me.RichTextBox2.TabIndex = 8
Me.RichTextBox2.Text = ""
'
'CheckBox3
'
Me.CheckBox3.AutoSize = True
Me.CheckBox3.Location = New System.Drawing.Point(151, 104)
Me.CheckBox3.Name = "CheckBox3"
Me.CheckBox3.Size = New System.Drawing.Size(142, 17)
Me.CheckBox3.TabIndex = 9
Me.CheckBox3.Text = "Input is RNA compliment"
Me.CheckBox3.UseVisualStyleBackColor = True
'
'TextBox3
'
Me.TextBox3.Location = New System.Drawing.Point(49, 179)
Me.TextBox3.Name = "TextBox3"
Me.TextBox3.Size = New System.Drawing.Size(100, 20)
Me.TextBox3.TabIndex = 10
Me.TextBox3.Text = "0"
'
'Label1
'
Me.Label1.AutoSize = True
Me.Label1.Location = New System.Drawing.Point(13, 156)
Me.Label1.Name = "Label1"
Me.Label1.Size = New System.Drawing.Size(58, 13)
Me.Label1.TabIndex = 12
Me.Label1.Text = "Trim bases"
'
'Label2
'
Me.Label2.AutoSize = True
Me.Label2.Location = New System.Drawing.Point(13, 182)
Me.Label2.Name = "Label2"
Me.Label2.Size = New System.Drawing.Size(34, 13)
Me.Label2.TabIndex = 13
Me.Label2.Text = "Front:"
'
'Label3
'
Me.Label3.AutoSize = True
Me.Label3.Location = New System.Drawing.Point(13, 216)
Me.Label3.Name = "Label3"
Me.Label3.Size = New System.Drawing.Size(35, 13)
Me.Label3.TabIndex = 14
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Me.Label3.Text = "Back:"
'
'TextBox4
'
Me.TextBox4.Location = New System.Drawing.Point(50, 213)
Me.TextBox4.Name = "TextBox4"
Me.TextBox4.Size = New System.Drawing.Size(100, 20)
Me.TextBox4.TabIndex = 15
Me.TextBox4.Text = "0"
'
'RichTextBox3
'
Me.RichTextBox3.Location = New System.Drawing.Point(12, 376)
Me.RichTextBox3.Name = "RichTextBox3"
Me.RichTextBox3.Size = New System.Drawing.Size(300, 80)
Me.RichTextBox3.TabIndex = 16
Me.RichTextBox3.Text = ""
'
'RichTextBox4
'
Me.RichTextBox4.Location = New System.Drawing.Point(13, 475)
Me.RichTextBox4.Name = "RichTextBox4"
Me.RichTextBox4.Size = New System.Drawing.Size(300, 80)
Me.RichTextBox4.TabIndex = 17
Me.RichTextBox4.Text = ""
'
'RichTextBox5
'
Me.RichTextBox5.Location = New System.Drawing.Point(12, 576)
Me.RichTextBox5.Name = "RichTextBox5"
Me.RichTextBox5.Size = New System.Drawing.Size(300, 80)
Me.RichTextBox5.TabIndex = 18
Me.RichTextBox5.Text = ""
'
'Label4
'
Me.Label4.AutoSize = True
Me.Label4.Location = New System.Drawing.Point(13, 252)
Me.Label4.Name = "Label4"
Me.Label4.Size = New System.Drawing.Size(82, 13)
Me.Label4.TabIndex = 19
Me.Label4.Text = "Variable Region"
'
'Label5
'
Me.Label5.AutoSize = True
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Me.Label5.Location = New System.Drawing.Point(13, 360)
Me.Label5.Name = "Label5"
Me.Label5.Size = New System.Drawing.Size(84, 13)
Me.Label5.TabIndex = 20
Me.Label5.Text = "Diversity Region"
'
'Label6
'
Me.Label6.AutoSize = True
Me.Label6.Location = New System.Drawing.Point(13, 459)
Me.Label6.Name = "Label6"
Me.Label6.Size = New System.Drawing.Size(77, 13)
Me.Label6.TabIndex = 21
Me.Label6.Text = "Joining Region"
'
'RichTextBox6
'
Me.RichTextBox6.Location = New System.Drawing.Point(590, 34)
Me.RichTextBox6.Name = "RichTextBox6"
Me.RichTextBox6.Size = New System.Drawing.Size(324, 620)
Me.RichTextBox6.TabIndex = 22
Me.RichTextBox6.Text = ""
'
'Label8
'
Me.Label8.AutoSize = True
Me.Label8.Location = New System.Drawing.Point(341, 16)
Me.Label8.Name = "Label8"
Me.Label8.Size = New System.Drawing.Size(85, 13)
Me.Label8.TabIndex = 24
Me.Label8.Text = "siRNA Rankings"
'
'Label9
'
Me.Label9.AutoSize = True
Me.Label9.Location = New System.Drawing.Point(593, 15)
Me.Label9.Name = "Label9"
Me.Label9.Size = New System.Drawing.Size(104, 13)
Me.Label9.TabIndex = 25
Me.Label9.Text = "siRNA with Promoter"
'
'Label10
'
Me.Label10.AutoSize = True
Me.Label10.Location = New System.Drawing.Point(13, 560)
Me.Label10.Name = "Label10"
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Me.Label10.Size = New System.Drawing.Size(86, 13)
Me.Label10.TabIndex = 26
Me.Label10.Text = "Constant Region"
'
'Label7
'
Me.Label7.AutoSize = True
Me.Label7.Location = New System.Drawing.Point(13, 17)
Me.Label7.Name = "Label7"
Me.Label7.Size = New System.Drawing.Size(136, 13)
Me.Label7.TabIndex = 27
Me.Label7.Text = "Input TCRb sequence here"
'
'Label11
'
Me.Label11.AutoSize = True
Me.Label11.Location = New System.Drawing.Point(13, 59)
Me.Label11.Name = "Label11"
Me.Label11.Size = New System.Drawing.Size(73, 13)
Me.Label11.TabIndex = 28
Me.Label11.Text = "siRNA Length"
'
'Form1
'
Me.AutoScaleDimensions = New System.Drawing.SizeF(6.0!, 13.0!)
Me.AutoScaleMode = System.Windows.Forms.AutoScaleMode.Font
Me.ClientSize = New System.Drawing.Size(926, 666)
Me.Controls.Add(Me.Label11)
Me.Controls.Add(Me.Label7)
Me.Controls.Add(Me.Label10)
Me.Controls.Add(Me.Label9)
Me.Controls.Add(Me.Label8)
Me.Controls.Add(Me.RichTextBox6)
Me.Controls.Add(Me.Label6)
Me.Controls.Add(Me.Label5)
Me.Controls.Add(Me.Label4)
Me.Controls.Add(Me.RichTextBox5)
Me.Controls.Add(Me.RichTextBox4)
Me.Controls.Add(Me.RichTextBox3)
Me.Controls.Add(Me.TextBox4)
Me.Controls.Add(Me.Label3)
Me.Controls.Add(Me.Label2)
Me.Controls.Add(Me.Label1)
Me.Controls.Add(Me.TextBox3)
Me.Controls.Add(Me.CheckBox3)
Me.Controls.Add(Me.RichTextBox2)
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Me.Controls.Add(Me.CheckBox2)
Me.Controls.Add(Me.CheckBox1)
Me.Controls.Add(Me.RichTextBox1)
Me.Controls.Add(Me.TextBox2)
Me.Controls.Add(Me.TextBox1)
Me.Controls.Add(Me.Button1)
Me.Name = "Form1"
Me.Text = "TCRb siRNA Solver"
Me.ResumeLayout(False)
Me.PerformLayout()
End Sub
Friend WithEvents Button1 As Button
Friend WithEvents TextBox1 As TextBox
Friend WithEvents TextBox2 As TextBox
Friend WithEvents RichTextBox1 As RichTextBox
Friend WithEvents CheckBox1 As CheckBox
Friend WithEvents CheckBox2 As CheckBox
Friend WithEvents RichTextBox2 As RichTextBox
Friend WithEvents CheckBox3 As CheckBox
Friend WithEvents TextBox3 As TextBox
Friend WithEvents Label1 As Label
Friend WithEvents Label2 As Label
Friend WithEvents Label3 As Label
Friend WithEvents TextBox4 As TextBox
Friend WithEvents RichTextBox3 As RichTextBox
Friend WithEvents RichTextBox4 As RichTextBox
Friend WithEvents RichTextBox5 As RichTextBox
Friend WithEvents Label4 As Label
Friend WithEvents Label5 As Label
Friend WithEvents Label6 As Label
Friend WithEvents RichTextBox6 As RichTextBox
Friend WithEvents Label8 As Label
Friend WithEvents Label9 As Label
Friend WithEvents Label10 As Label
Friend WithEvents Label7 As Label
Friend WithEvents Label11 As Label
End Class
8.2 Non-interface source code
Public Class Form 1
'Halts current proceedure and throws error to the user
Sub Throw_error()
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MsgBox("An error has occured. Please check your inputs and try again.")
Stop
End Sub
'Scans respective siRNA regions for whether or not they meet The first Descrim as defined by
Reynalds et al
'SiRNA has a base of A in position 3
'Returns a boolean value
Function Discrim1(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
'Checks specified position for specified character
If GetChar(siRNA, 3) = "a" Or GetChar(siRNA, 3) = "A" Then
bool = True
End If
Return bool
End Function
'Scans respective siRNA regions for whether or not they meet The second Descrim as defined by
Reynalds et al
'SiRNA has a base of A in position 19
'Returns a boolean value
Function Discrim2(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
'Checks specified position for specified character
If GetChar(siRNA, 19) = "a" Or GetChar(siRNA, 19) = "A" Then
bool = True
End If
Return bool
End Function
'Scans respective siRNA regions for whether or not they meet the third Descrim as defined by
Reynalds et al
'SiRNA does not have a base of G in position 13
'Returns a boolean value
Function Discrim3(ByVal siRNA As String) As Boolean
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Dim bool As Boolean = False
'Checks specified position for specified character
If Not GetChar(siRNA, 13) = "g" And Not GetChar(siRNA, 13) = "G" Then
bool = True
End If
Return bool
End Function
'Scans respective siRNA regions for whether or not they meet the fourth Descrim as defined by
Reynalds et al
'SiRNA has a base of U in position 10
'Returns a boolean value
Function Discrim4(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
'Checks specified position for specified character
If GetChar(siRNA, 10) = "u" Or GetChar(siRNA, 10) = "U" Then
bool = True
End If
Return bool
End Function

'Scans respective siRNA regions for whether or not they meet the fifth Descrim as defined by
Reynalds et al
'SiRNA does not have a base of C or G in position 19
'Returns a boolean value
Function Discrim5(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
'Checks specified position for specified character
If Not GetChar(siRNA, 19) = "c" And Not GetChar(siRNA, 19) = "C" And Not
GetChar(siRNA, 19) = "g" And Not GetChar(siRNA, 19) = "G" Then
bool = True
End If
Return bool
End Function
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'Checks a substring of each siRNA for a palindromic sequence encompassing of 4 bases
'Returns a boolean value
Function Palindrome_check_4_units(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
Dim reverse_sequence As String = Strings.StrReverse(siRNA)
Dim count As Integer = 0
Dim forward As String = Nothing
Dim reverse As String = Nothing
'Splits sequence into substrings and compares them against their compliment
Do While count < siRNA.Length - 4
forward = siRNA.Remove(0, count)
forward = siRNA.Substring(0, 4)
Dim count2 As Integer = 0
Do While count2 < siRNA.Length - 4
reverse = siRNA.Remove(0, count)
reverse = siRNA.Substring(0, 4)
If forward = reverse Then
bool = True
End If
count2 = count2 + 1
Loop
count = count + 1
Loop
Return bool
End Function
'Checks a substring of each siRNA for a palindromic sequence encompassing of 5 bases
'Returns a boolean value
Function Palindrome_check_5_units(ByVal siRNA As String) As Boolean
Dim bool As Boolean = False
Dim reverse_sequence As String = Strings.StrReverse(siRNA)
Dim count As Integer = 0
Dim forward As String = Nothing
Dim reverse As String = Nothing
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'Splits sequence into substrings and compares them against their compliment
Do While count < siRNA.Length - 5
forward = siRNA.Remove(0, count)
forward = siRNA.Substring(0, 5)
Dim count2 As Integer = 0
Do While count2 < siRNA.Length - 5
reverse = siRNA.Remove(0, count)
reverse = siRNA.Substring(0, 5)
If forward = reverse Then
bool = True
End If
count2 = count2 + 1
Loop
count = count + 1
Loop
Return bool
End Function
'Checks for the GC content of an siRNA input
'Returns a value between 0 and 1
Function Get_GC(ByVal siRNA As String, siRNA_length As Integer) As Double
Dim GC_content As Double = 0
Dim count As Integer = 0
Dim ATU_count As Integer = 0
Do While count < siRNA.Length
If GetChar(siRNA, count + 1) = "a" Or GetChar(siRNA, count + 1) = "A" Or
GetChar(siRNA, count + 1) = "t" Or GetChar(siRNA, count + 1) = "T" Or GetChar(siRNA,
count + 1) = "u" Or GetChar(siRNA, count + 1) = "U" Then
ATU_count = ATU_count + 1
End If
count = count + 1
Loop
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GC_content = 1 - (ATU_count / siRNA_length)
Return GC_content
End Function
'Checks whether or not an A or U is present in positions 15-19 as specified in Reynalds et al
'Returns boolean value
Function AUT_in_15_through_19(ByVal sirna As String, sirna_ength As Integer) As Boolean
Dim bool As Boolean = False
'Load characters from siRNA into variables
Dim char15 As Char = GetChar(sirna, 15)
Dim char16 As Char = GetChar(sirna, 16)
Dim char17 As Char = GetChar(sirna, 17)
Dim char18 As Char = GetChar(sirna, 18)
Dim char19 As Char = GetChar(sirna, 19)
'Check above variables for presence of A, U, or T
If char15 = "a" Or char15 = "A" Or char15 = "t" Or char15 = "T" Or char15 = "u" Or char15 =
"U" Then
bool = True
End If
If char16 = "a" Or char16 = "A" Or char16 = "t" Or char16 = "T" Or char16 = "u" Or char16 =
"U" Then
bool = True
End If
If char17 = "a" Or char17 = "A" Or char17 = "t" Or char17 = "T" Or char17 = "u" Or char17 =
"U" Then
bool = True
End If
If char18 = "a" Or char18 = "A" Or char18 = "t" Or char18 = "T" Or char18 = "u" Or char18 =
"U" Then
bool = True
End If
If char19 = "a" Or char19 = "A" Or char19 = "t" Or char19 = "T" Or char19 = "u" Or char19 =
"U" Then
bool = True
End If
Return bool
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End Function
'Checks for a leading sequence of AA at the start of respective siRNA
'returns boolean value
Function Check_for_AA(ByVal siRNA As String) As Boolean
Dim AA_Bool As Boolean = False
Dim Score As Integer = 0
'For each A in the first two residues, the variable "score" is iterated by 1
If GetChar(siRNA, 1) = "A" Or GetChar(siRNA, 1) = "a" Then
Score = Score + 1
End If
If GetChar(siRNA, 2) = "A" Or GetChar(siRNA, 2) = "a" Then
Score = Score + 1
End If
'Score being equal to 2 indicated that both of the leading residues Is A
If Score = 2 Then
AA_Bool = True
End If
Return AA_Bool
End Function
'Checks for running sequences of A or T (variouse literature indicates that this can cause
dissociation of siRNA from RISC)
'returns boolean value
Function Check_for_running_T_or_A(ByVal siRNA As String, sirna_length As Integer) As
Boolean
Dim Poly_T_A As Boolean = False
Dim count As Integer = 0
Dim tempstring As String = Nothing
Do While count < sirna_length - 4
tempstring = siRNA
tempstring = tempstring.Remove(0, count) 'remove leading characters in temporary string
tempstring = tempstring.Substring(0, 4) ' trims temporary string to 4 characters
'Checks for a polly A or poly T sequence
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If tempstring = "aaaa" Or tempstring = "AAAA" Or tempstring = "TTTT" Or tempstring =
"tttt" Or tempstring = "UUUU" Or tempstring = "uuuu" Then
Poly_T_A = True
count = 9999999 'breaks loop
End If
count = count + 1
Loop
Return Poly_T_A
End Function
'Converts an input of a DNA sequence into its reverse complimentary RNA counterpart
'Returns string a value
Function Convert_to_RNA(Input As String)
Dim Sequence(Input.Length) As String
Dim Working_String(Input.Length) As String
Dim count As Integer = 0
'Loads input into an array for conversion
Do While count < Input.Length
Sequence(count) = Input(count)
count = count + 1
Loop
'Reverses the DNA input (this is important because we are interested in the reverse
compliment sequence)
Array.Reverse(Sequence)
count = 1
Dim Return_string As String = Nothing
'Converts first array sequence into complimentary values for second array
Do While count < Working_String.Length - 1
Select Case Sequence(count)
Case "A"
Working_String(count) = "U"
Case "a"
Working_String(count) = "U"
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Case "T"
Working_String(count) = "A"
Case "t"
Working_String(count) = "A"
Case "C"
Working_String(count) = "G"
Case "c"
Working_String(count) = "G"
Case "G"
Working_String(count) = "C"
Case "g"
Working_String(count) = "C"
Case Else
Throw_error()
End Select
count = count + 1
Loop
count = 0
'Converts array of characters into a normal string for the function to return
Do While count < Working_String.Length
Return_string = Return_string + Working_String(count)
count = count + 1
Loop
Return Return_string
End Function

'Converts an input of a RNA sequence into its reverse complimentary RNA counterpart
'Returns string a value
Function Convert_to_Compliment(Input As String)
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Dim Sequence(Input.Length) As String
Dim Working_String(Input.Length) As String
Dim count As Integer = 0
'Loads input into an array for conversion
Do While count < Input.Length
Sequence(count) = Input(count)
count = count + 1
Loop
'Reverses the DNA input (this is important because we are interested in the reverse
compliment sequence)
Array.Reverse(Sequence)
count = 1
Dim Return_string As String = Nothing
'Converts first array sequence into complimentary values for second array
Do While count < Working_String.Length - 2
Select Case Sequence(count)
Case "A"
Working_String(count) = "U"
Case "a"
Working_String(count) = "U"
Case "U"
Working_String(count) = "A"
Case "u"
Working_String(count) = "A"
Case "t"
Working_String(count) = "A"
Case "T"
Working_String(count) = "A"
Case "C"
Working_String(count) = "G"
Case "c"
Working_String(count) = "G"
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Case "G"
Working_String(count) = "C"
Case "g"
Working_String(count) = "C"
Case Else
Throw_error()
End Select
count = count + 1
Loop
count = 0
'Converts array of characters into a normal string for the function to return
Do While count < Working_String.Length
Return_string = Return_string + Working_String(count)
count = count + 1
Loop
Return Return_string
End Function
'Checks that values within text boxes are of the data type needed
'Calls Throw_error() sub-procedure if any of the tests are positive
Sub Error_Checks()
TextBox1.Text.ToUpper()
Dim Check_TB2 As Integer
If Not Integer.TryParse(TextBox2.Text, Check_TB2) Then
Throw_error()
End If
Dim Check_TB3 As Integer
If Not Integer.TryParse(TextBox3.Text, Check_TB3) Then
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Throw_error()
End If
Dim Check_TB4 As Integer
If Not Integer.TryParse(TextBox4.Text, Check_TB4) Then
Throw_error()
End If
End Sub
'Sequence of events called when User hits the "Run" button
Private Sub Button1_Click(sender As Object, e As EventArgs) Handles Button1.Click
'Resets output
RichTextBox1.Text = Nothing
Region "Trim nucleic acid sequence"
'Trims front of siRNA sequence if specified by user to do so
If Not TextBox2.Text = Nothing Then
Dim FrontTrim As Integer = CInt(TextBox3.Text)
TextBox1.Text = TextBox1.Text.Remove(0, FrontTrim)
End If
'Trims back of siRNA sequence if specified by user to do so
If Not TextBox3.Text = Nothing Then
Dim BackTrim As Integer = CInt(TextBox4.Text)
Dim TempVar As Integer = TextBox1.Text.Length
TextBox1.Text = TextBox1.Text.Substring(0, TempVar - BackTrim)
End If
End Region
'Calls subprocedure to convert input from a DNA sequence to a reverse complimentary RNA
sequence if specified by user
If CheckBox2.Checked Then
TextBox1.Text = Convert_to_RNA(TextBox1.Text)
End If
'Calls subprocedure to convert input from a RNA sequence to a reverse complimentary RNA
sequence if specified by user
If CheckBox3.Checked Then
TextBox1.Text = Convert_to_Compliment(TextBox1.Text)
End If
Dim SiRNA_Score As Integer = 0
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'Initializes arrays which tore siRNA candidates and their corresponding scores
Dim DataArray(50000) As String
Dim ScoreArray(50000) As Double
Dim codelength As Integer = 0
codelength = TextBox1.Text.Length
Dim SiRNA_Length = Convert.ToInt32(TextBox2.Text)
Dim count As Integer = 0

'Loads siRNA candidates into an array of length specified by user
Region "Load siRNA Array"
Do While count < codelength - SiRNA_Length 'load siRNAs into array
DataArray(count) = TextBox1.Text
DataArray(count) = DataArray(count).Remove(0, count) 'remove leading characters in
string
DataArray(count) = DataArray(count).Substring(0, SiRNA_Length) 'remove following
characters after siRNA
count = count + 1
Loop
End Region
count = 0
'Seperates V, D, J, and C regions
Region "separate regions"
If Not CheckBox1.Checked Then
Do While TextBox1.Text.Length > count
If count <= 340 Then
RichTextBox2.Text = RichTextBox2.Text + GetChar(TextBox1.Text, count + 1)
End If
If count > 340 And count <= 356 Then
RichTextBox3.Text = RichTextBox3.Text + GetChar(TextBox1.Text, count + 1)
End If
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If count > 356 And count <= 406 Then
RichTextBox4.Text = RichTextBox4.Text + GetChar(TextBox1.Text, count + 1)
End If
If count > 406 Then
RichTextBox5.Text = RichTextBox5.Text + GetChar(TextBox1.Text, count + 1)
End If
count = count + 1
Loop
End If
End Region
count = 0
'Adds scores
'Values added to each siRNA score are largely determined by their level of significance'-RNAi as determined by Reynalds et al
Region "Tally Scores"
Do While count < codelength - SiRNA_Length
'calls function to determine GC content of siRNA
Dim GC_content As Double = Get_GC(DataArray(count), SiRNA_Length)
If Discrim1(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 16.8
End If
If Discrim2(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 22.1
End If
If Discrim3(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 14.1
End If
If Discrim4(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 30.6
End If
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If Discrim5(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 25.6
End If
If not Palindrome_check_4_units(DataArray(count)) And not
Palindrome_check_5_units(DataArray(count)) Then
SiRNA_Score = SiRNA_Score + 10.1
End If
If AUT_in_15_through_19(DataArray(count), DataArray(count).Length) Then
SiRNA_Score = SiRNA_Score + 16.9
End If
'SiRNA with running A or T regions are not candidates for successful inhibition
If Check_for_running_T_or_A(DataArray(count), DataArray(count).Length) Then
'Lowers score to a level where they will be ignored by future algorithms
SiRNA_Score = SiRNA_Score - 20000
End If
'SiRNA with running A or T regions are not candidates for successful inhibition
If Not Check_for_AA(DataArray(count)) Then
'Lowers score to a level where they will be ignored by future algorithms
SiRNA_Score = SiRNA_Score - 20000
End If
'SiRNA with running A or T regions are not candidates for successful inhibition
If Get_GC(DataArray(count), DataArray(count).Length) < 0.3 Or
Get_GC(DataArray(count), DataArray(count).Length) > 0.52 Then
'Lowers score to a level where they will be ignored by future algorithms
SiRNA_Score = SiRNA_Score - 20000
End If
ScoreArray(count) = SiRNA_Score
SiRNA_Score = 0
count = count + 1
Loop
End Region
'Sorts array in accending order based on the assigned score
Array.Sort(ScoreArray, DataArray)
'Reverses array so it will be sequenced in decending order for the user
Array.Reverse(ScoreArray)
Array.Reverse(DataArray)
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count = 0
'Displays resulting siRNA candidates and their respective scores to the user
Do While count < codelength - SiRNA_Length
If ScoreArray(count) > 0 Then
'Displays siRNA candidate with respective score adjacent
RichTextBox1.Text = RichTextBox1.Text + DataArray(count) + " " +
ScoreArray(count).ToString + vbCrLf
'Displays siRNA candidate with the promoter sequence added
RichTextBox6.Text = RichTextBox6.Text + DataArray(count) + "CCTGTCTC" + "
" + ScoreArray(count).ToString + vbCrLf
'Removes leading AA to get compliment without overhang
DataArray(count).Remove(0, 2)
'Displays compliment and adds promoter sequence as well as AA overhang to the
compliment
RichTextBox6.Text = RichTextBox6.Text + "AA" +
Convert_to_Compliment(DataArray(count)) + "CCTGTCTC" + vbCrLf + vbCrLf
End If
count = count + 1
Loop
End Sub
End Class
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